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ABSTRACT 
 
Colorectal cancer has been reported as the third leading cause of cancer related death in the 
world.  About 5-10% of colorectal cancers are due to an inherited predisposition.  
This thesis focuses on investigating the prevalence of large genomic rearrangements and other 
types of germline mutations in novel cancer susceptibility genes in two major hereditary 
colorectal cancer syndromes, hereditary nonpolyposis colorectal cancer (HNPCC) and familial 
adenomatous polyposis (FAP). Furthermore, the second somatic mutations were characterized in 
the tumors from DNA mismatch repair (HNPC) and APC gene mutation carriers (FAP) to address 
the mechanism(s) of tumorigenesis in these two syndromes.  All these investigations aim to 
understand tumor initiation and progression in hereditary colorectal cancer syndromes in order to 
enable early and reliable presymptomatic diagnosis of a person at increased risk and offer optimal 
medical management to prevent cancer. 
HNPCC is an autosomal dominantly inherited cancer predisposition syndrome caused by 
germline mutations in DNA mismatch repair (MMR) genes. Prescreening methods are routinely 
applied to detect MMR gene sequence alterations, but inevitably miss large genomic 
rearrangements. Here, two novel PCR-based methods to study gene dosage were introduced in 35 
MLH/MSH2 HNPCC patients in whom no mutation could be identified by conventional 
screening methods. These methods are QMPA (quantitative multiplex PCR amplification) and 
MLPA (multiplex ligation dependent probe amplification). Three patients were found to carry 
large deletions by QMPA and MLPA. In 1 patient, however, QMPA yielded a false positive 
result. Both methods, QMPA and MLPA appear to be of comparable sensitivity albeit with 
different specificity. Since the QMPA technique is difficult to set up and to standardize the PCR 
conditions, the MLPA assay is better suited to routinely search for large genomic rearrangements. 
The investigations subsequently continued to detect the frequency and nature of LOH as second, 
somatic event in tumors from MLH/MSH2 germline deletion carriers. MLPA technique was 
applied to analyze 18 cancer specimens from two independent sets of Swiss and Finnish 
MLH1/MSH2 deletion carriers. Results revealed that somatic deletions identical to the ones in the 
germline occur frequently (55%) in CRCs and that this type of loss of the wild type allele is also 
present in extracolonic HNPCC associated tumors. Chromosome specific marker analysis implies 
that loss of the wild type allele predominantly occurs through locus restricted recombination 
events, i.e. gene conversion, rather than mitotic recombination or deletion of the respective gene 
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locus. The same investigation was carried on a 31 years old colorectal cancer patient who carries 
de novo mutation (c.666dupA) in the MLH1 gene. The tumor analysis of this patient showed a 
similar somatic mutation mechanism to the large genomic deletion carriers.  
Prior to our analysis of the somatic hits in the attenuated form of familial adenomatous polyposis 
(AFAP), earlier investigations had shown that in classical FAP the "two hits" in the APC 
(Adenomatosis polyposis coli) gene are not occurring randomly but are in fact interdependent. 
AFAP is clinically characterized by fewer than 100 adenomatous polyps in the colorectum and 
presents with a milder phenotype compared to classical FAP. APC mutations in AFAP patients 
are typically located in the very 5’ and 3’ gene regions as well as in the alternatively spliced 
region of exon 9. In a collaborative effort we investigated the somatic alterations in 235 tumors of 
35 AFAP patients. Adenomas of AFAP patients were often found to actually exhibit ‘three hits’ 
at the APC gene that mostly result in loss of the allele carrying the germline APC mutation. We 
assume that this actually leads to an optimization of the beta-catenin level, hence positively 
regulating the Wnt signal. 
Recently, bi-allelic germline mutations in the base excision repair gene MutY homologue (MYH) 
have been associated with an autosomal recessively inherited predisposition to multiple colorectal 
adenomas. They are also referred to as MYH-associated polyposis (MAP). Here, we assessed the 
prevalence of MYH germline alteration in 79 unrelated polyposis patients in whom no APC 
mutation could be detected. The aims of the study were i) to assess the MYH mutation carrier 
frequency among Swiss APC mutation negative patients and (ii) to identify phenotypic 
differences between MYH mutation carriers and APC / MYH mutation negative polyposis patients. 
dHPLC and direct genomic DNA sequencing were applied to screen for mutation. Overall, 7 
biallelic and 9 monoallelic MYH germline mutation carriers were identified. 1 out of 10 classical 
polyposis and 6 out of 35 attenuated polyposis patients carried biallelic MYH alterations, 2 of 
which represent novel gene variants (p.R 171q and p.R 231H). On the basis of our finding and 
earlier reports, MYH mutation screening should be considered if all of the following criteria are 
fulfilled: (1) presence of classical or attenuated polyposis coli, 2) absence of a pathogenic APC 
mutation, and 3) a family history compatible with an autosomal recessive mode of inheritance.
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CHAPTER 1 
1. General Introduction 
1.1 Cancer and Colorectal Cancer (CRC) 
Cancer is a common and devastating disease and remains one of the most serious public health 
issues. Despite recent progress in its treatments, so far few types are curable. Thus, cancer is 
under intense research because of the high prevalence and severe consequences leading to death. 
Most research aims to apply the knowledge about cancer in order to allow early diagnosis and 
understanding the mechanism of tumor development. The vast majority of cancers are considered 
to be sporadic and not primarily due to an inherited susceptibility, but there are 5-10 % of cancers 
are caused by inherited genetic changes [1, 2]. With the new technologies of molecular biology, it 
is possible to assess disease risk and guide genetic screening to prevent cancer and achieve 
successful cancer treatments.  
Colorectal cancer is a disease characterized by the development of malignant cells in the lining or 
epithelium of the colon and rectum (http://www.cancer.gov). So far, an estimated 145,290 new 
cases are diagnosed worldwide, and 56,600 deaths from colorectal cancer will occur every year 
[3]. It is the third leading cause of cancer related death in most Western countries [4, 5]. Genetic 
researchs provided the possibility to identify persons at high risk for colorectal cancer because of 
an inherited predisposition to develop this malignancy [6]. Regular endoscopy is used as 
screening method to detect the presence of polyps at an early stage, thus prevent CRC 
development and detecting and treating early-stage cancers can lower the mortality rate for 
colorectal cancer [7, 8]. 
About 20% of CRC patients have a family history of colorectal cancer that suggests the influence 
of genetic factors [5]. Five-6% of CRCs occur are due to an inherited genetic predisposition. It is 
clear that other non-identified genes and background genetic factors contribute to the 
development of colorectal cancer, in conjunction with non-genetic risk factors, e.g. environmental 
factors, diet, etc [9].  
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1.2 Hereditary Colorectal Cancers 
Hereditary CRCs can be divided into two distinct categories: Predisposition to colon cancer 
without and with pre-existing polyposis. 
[1] Predisposition to colon cancer without pre-existing polyposis syndromes 
Include hereditary nonpolyposis colon cancer (HNPCC) syndrome, Muir-Torre syndrome and 
Turcot syndrome (associated with glioblastoma) [10-13]. These syndromes are mainly caused by 
MMR gene mutations.  
[2] Predisposition to colon cancer with pre-existing polyposis  
Include adenomatous polyposis and harmartomatous polyposis syndromes. Adenomatous 
polyposis syndromes include familial adenomatous polyposis syndrome (FAP) and its variant 
attenuated familial adenomatous polyposis (AFAP) [14, 15] [16], MYH-associated polyposis 
(MAP), Gardner syndrome (variant of FAP) [17, 18]. In harmatomatous polyposis syndromes, the 
intestinal hamatomatous polyps are obligatory components of four inherited conditions: Peutz-
Jeghers syndrome, Juvenile Polyposis syndrome, Cowden disease and its variant, the Bannayan-
Ruvalcaba-Riley syndrome.  
The genes associated with the above syndromes have been well identified (see Table 1.1). 
 
Table 1.1  Genes associated with risk of different Hereditary Colorectal Cancer Syndromes 
Syndrome  Genes  Mean age at diagnosis 
Familial Adenomatous 
Polyposis (FAP) 
 APC  Age 40y [19] 
Hereditary Nonpolyposis 
Colorectal Cancer (HNPCC) 
Mismatch Repair 
(MMR) Genes, 
e.g..MLH1,MSH2 ,etc 
Age 42y [20, 21] 
MYH associated polyposis 
(MAP) 
MYH  Age 46y [10] 
Juvenile Polyposis syndrome SMAD4, PTEN, 
BMPR1A 
Age 35y [24, 25] 
Cowden Syndrome and 
Bannayan-Ruvalcaba-Riley 
syndrome 
PTEN Age 38-46y [25-27] 
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 1.2.1 Predisposition to Colon Cance r without Pre-Existing Polyposis - Hereditary 
Nonpolyposis Colorectal Cancer (HNPCC)  
HNPCC originally called “cancer family syndrome” or “Lynch syndrome” [28], accounts for 
about 2% to 5% of all colorectal cancers. Most HNPCC patients do not have numbers of polyps. 
It is caused by germline mutation in one of the mismatch repair genes (MMR) and is inherited in 
an autosomal dominant fashion. The mean age of cancer diagnosis is approximately 42 years (see 
Table 1.1) compared with 64 years in sporadic colorectal cancer [6, 29]. About 70% of HNPCC 
cancers develop in the proximal side of colon, coecum to transverse colon [30]. 
Associated extracolonic cancers are often found in HNPCC patients.  These include cancer of the 
endometrium, stomach, ovary, ureter and renal pelvis, hepatobiliary tract, brain (Turcot-
syndrome); sebaceous gland (Muir-Torre syndrome) as well as carcinoma of the small bowel [31-
34]. 
Genetic testing of HNPCC 
To define HNPCC families, the Amersterdam criteria I were established with the goal to identify 
the molecular basis of this disease on common clinical framework by the International 
collaborative group (ICG) in 1990 [35]. 10 years later, in order to improve the diagnosis of 
HNPCC clinically, ICG developed revised criteria - Amersterdam Criteria II to appreciate the 
HNPCC families who carry germline mutation of mismatch repair genes and have extracolonic 
cancers but do not meet the Amsterdam Criteria I [36]. In 1996, the Bethesda Guidelines were 
proposed for selection of patients whose tumors should be tested for microsatellite instability 
(MSI) [37]. This guideline was updated recently to so called revised Bethesda Guidelines [38, 
39].  
HNPCC results from germline mutation of one of several DNA mismatch repair (MMR) genes 
[11, 13]. These genes are essential to maintain the fidelity of DNA during replication. Mutation 
of these genes results in deficient DNA mismatch repair activity. These genes include MLH1 
(human mutL homolog 1), MSH2 (human mutS homolog 2) [40], PMS1 and PMS2 (human 
postmeiotic segregation 1 and 2) [11] and MSH6 (human mutS homolog 6) .  
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In HNPCC patients with a MMR gene mutation, 90% of mutations are found in MLH1 and 
MSH2 and approximately 10% patients carry MSH6 mutations [41]. Clinical features of HNPCC 
are tightly related with the 
 
The mismatched nucleotides 
were introduced into the newly 
replicated strand.  
 
MSH (MSH2/MSH6, 
MSH2/MSH3) heterodimers 
recognize the mismatch loop 
formed by ATP and ADP.  
 
 
 
MLH (MLH/PMS) protein  
interacts with ATP-bound 
MSH clamps and signal is 
transferred. 
 
 
Helicase recognizes and 
replace the incised DNA strand 
 
Single Strand DNA (ssDNA) 
is captured. 
 
 
 
 
 
Mismatched nucleotides 
containing strands are elimated 
by exonucleases (EXO I)  
 
 
 
 
 
 
Replication complex re-
synthesis excised strand, error 
was repaired 
 
Figure 1.1: Molecular Switch Model of Mismatch Repair [45]  
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mutation of these MMR genes (see Table 1.2). These MMR genes form different heterodimers 
(see Table 1.2) to participate in the mismatch repair process (see Figure 1. 1). All MMR gene 
mutation carriers are at a 50% risk of passing the altered gene to their offspring according to the 
mechanism of autosomal dominant inheritance [42] . 
Understanding the basic function of these MMR genes is essential to better understand the 
mechanisms of HNPCC development and develop methods for detecting these gene mutations 
[43]. Basically, the primary function of the MMR pathway is responsible for the recognition and 
correcting of the mispairing of DNA nucleotides bases and the insertions or deletions that are 
frequently present during normal replication. It is essential to maintain fidelity of genomic DNA 
[44]. Haploinsufficient cells have normal or nearly normal repair activity, but inactivation of both  
alleles of MMR genes will result in loss of DNA repair activity [21].   
 Table 1.2: Clinical features associated with germline mutations in the MMR genes 
associated with a predisposition to HNPCC 
Gene Chromosome 
Locus 
Heterodimer Phenotypic features of HNPCC Total 
numbers of 
Mutations * 
MLH1 3p21.3[12] MutL homologue 1 
protein. Interact With 
PMS2, MLH3, 
PMS1, MLH2 
Typical HNPCC, 30% of 
mutations are of the missense 
type whose phenotypic 
manifestations may vary [49] 
[30]. 
409 
MSH2 2p22-p21[42] MutS homolgues 
protein 2. Interact 
with MSH3 and 
MSH6 
Typical HNPCC. Patients have 
more extracolonic cancer than 
in MLH1 mutations carriers. Is 
also the major gene underlying 
Muir-Torre syndrome[30]. 
337 
MSH6 2p16[50] MutS homologues 6 
protein. Interact with 
MSH2 
Typical or atypical HNPCC. 
Late CRC onset, frequent 
occurrence of endometrial 
cancer, distal location of colon 
cancers and low degree of MSI 
in tumors [51]. 
81 
PMS2 7p22[11] Human postmeiotic 
segregation 2 protein. 
Interact with MLH1. 
Typical or atypical HNPCC. 
The penetrance of mutations 
may vary [11] 
11 
MLH3  14q24.3[52] MutL homologue 3.  
Interact with MLH1. 
Majority are missense 
mutations. Atypical HNPCC. 
11 
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 Characteristic as distal location 
of colorectal cancers [52] 
 
*These data are extracted from Human Gene Mutation Database at the Institute of Medical 
Genetics in Cardiff (http://www.hgmd.org), May, 2006 
This hypermutable state within the cell has been shown by the insertion or deletion of 
monoucleotide, dinucleotide, or trinucleotide base pair repeats in the microstatellite tracts in the 
tumor DNA [46]. Microsatellite sequences are short repetitive sequences throughout the genome 
[47]. When these sequences are not replicated correctly and not repaired by the MMR proteins, 
this is called microsatellite instability (MSI). MSI can be detected in around 90% of colorectal 
cancers from individuals with HNPCC. It has been suggested that mutations in the human 
mismatch repair genes are responsible for the MSI of the HNPCC tumors [48].  
Based on all the knowledge of MMR genes, immunohistochemistry (IHC) and MSI analysis are 
the first round molecular testing performed in the tumor of HNPCC patients [29, 53]. IHC is a 
simple assay to screen the protein expression of MMR genes. Loss of expression in any of these 
proteins suggests germline mutation analysis [54, 55]. If the tumor exhibits MSI, germline 
mutation will be considered [56].  
Commercial sequence testing is available to search for mutations in MLH1 and MSH2.  Clinical 
and cost consideration may guide testing strategies. MLPA and multiplex PCR, southern blot are 
the methods applied to detect genomic deletion or duplication after sequencing fails to detect the 
mutation [57]. Once a genetic alteration has been identified in a HNPCC family, the same 
alteration is easier to be tested for in other affected family members [58].  
1.2.2 Predisposition to colon cancer with pre-existing polyposis – Familial adenomatous 
polyposis (FAP) and MYH associated polyposis (MAP) 
FAP is one of the most clearly defined disorders, characterized by hundreds to thousands of 
polyps in the colon and rectum, which usually develop during late childhood or early adult life 
[59]. Extracolonic manifestations are variably present, such as osteromas, epidermoid cysts, 
desmoids, congenital hypertrophy of retinal pigment epithelium (CHRPE) and other cancers [60, 
61]. Attenuated FAP (AFAP) is characterized by the presence of fewer less than 100 
adenomatous polyps and later clinical manifestation [62]. FAP and AFAP are comparatively rare, 
representing about 0.5-1% of all CRCs [63]. 
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Genetic testing of FAP and AFAP 
FAP is due to mutations of the adenomatous polyposis coli (APC) gene. The APC gene is located 
at chromosome 5q21 and encompasses 15 exons. Exon15 comprises 75% of the coding sequence 
and is also the position where mutations most commonly occur. 
The APC gene is a tumor suppressor gene which encodes a multifunction protein of 2843 amino 
acids (Figure 1.2).  It is involved into the Wnt singalling pathway. The aberrant activation of Wnt 
pathway is considered as a major oncogenic mechanism for many tumor types. In FAP, the 
mutation of APC leads to the degredation of ß-catenin [64]. About 682 different disease 
associated germline mutatios in the APC gene have aleady been described (www.hgmd.org). The 
clinical features of FAP appear to be generally associated with the location of the mutation in the 
APC gene and the type of mutation (framshift and missense mutation or large deletion). In Table 
1.2, the major mutations and their related phenotypes are summarized. Genotype-phenotype 
correlations are useful in increasing the accuracy and effectiveness of screening, surveillance and 
treatment [65, 66], e.g. mutation at codon 1309 (a deletion of AAAG in the 1309 codon) is the 
most frequently observed mutation ( in 10% of FAP patients) and associated with severe colonic 
polyposis. (Table 1.3 and Figure 1.2) 
Table 1.3:  Mutation site and their phenotype in APC gene [67] 
Codons 457 and 1444 CHRPE (congenital hypertrophy of the 
retinal pigment epithelium ) 
Codons 1250-1464(mutation cluster 
region) 
Severe FAP, develop >5000 polyps 
Codon 1309 Severe phenotype 
Codons 1403-1578  Desmoid 
5' and 3'end, exon 9 Attenuated polyposis, develop <100 polyps 
Although an APC mutation is responsible for most of FAP families, there are some families that 
display the phenotype of classical FAP or AFAP syndrome without APC mutations. MAP 
(MutYH-associated polyposis) is a recently described colorectal adenoma and carcinoma 
predisposition syndrome that is associated with inherited mutations of the human MutY 
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homologue gene (MYH). It is associated with 10-100 polyps. MAP is inherited in an autosomal 
recessive manner [10]. 
MYH is a base-excision-repair gene, which encodes a monofunctional BER glycosidase that is 
capable of correcting oxidative DNA damage. Failure to correct this damage can lead to the 
formation of 8-oxoG, causing an increase in G:C/T:A transversions. It has been reported that 
germline MYH mutations cause approximately 1-3% of all unselected colorectal cancers [68, 69]. 
All these findings have important implications for accurate genetic testing of the patients without 
APC germline mutation who have less than 100 adenomas. 
Genetic testing for APC and MYH alterations are performed on leukocyte-derived DNA of the 
patients. There are several methods applied so far, e.g. direct sequencing, mutation screening 
with single strand conformational polymorphism (SSCP), denaturing gradient gel 
electrophoresis (DGGE), protein truncation test (PTT), denaturing high performance liquid 
chromatography (dHPLC) and multiplex ligation-dependent probe amplification (MLPA).  
 
Figure 1.2: Structural features of the APC protein. Most of the mutations in APC occur in the 
mutator cluster region (MCR) and create truncated proteins. The truncated proteins contain ASEF and β-
catenin binding sites in the armadillo-repeat domain but looses the β-catenin regulatory activity which is 
located in the 20-amino acids repeat domain. Somatic mutations are selected more frequently in FAP 
patients with germ-line mutations outside of the MCR [72] [73]. 
Since the majority of APC mutations result in the formation of a truncated APC protein product, 
the PTT is the first screening method for genetic testing. With rigorous PTT testing and the use 
of other screening methods, 90% of mutations can be detected in classical FAP [70]. If an APC 
 Chapter 1   
 
9 
pathogenic mutation is detected in the index patient, the same APC mutation will be found in all 
affected family members [71]. If there is no APC mutation found in the classical FAP and AFAP 
phenotype, MYH mutation screening is performed within in these patients [58].  
 
1.3 Tumorigenesis of Colorectal Cancers 
Colorectal cancer develops as a result of the pathologic transformation of normal colonic 
epithelium to adenomas of progressively larger size and ultimately to an invasive cancer. Fearon 
and Vogelstein proposed a multistep progression model in 1990 (adenoma-carcinoma sequence 
model) [74]. This multistep progression requires years and is accompanied by a number of 
genetic alterations in tumor suppressor genes and oncogenes, which contribute to the 
development of the malignant phenotype [75]. A morphological transition corresponding to the 
genetic mutations from normal colonic mucosa to a benign tumor (adenoma) and to a malignant 
carcinoma can be observed [74]. (Figure 1. 3)  
At least two pathways leading to colon cancer development are identified. They are 
“gatekeeper” and “caretaker” pathways (Figure 1. 4), which are initiated by “gatekeeper” genes 
and “caretaker” genes[76].  
“Caretaker” genes and “Gatekeeper” genes were distinct by Kinzler and Vogelstein in the 
determination of cancer in 1997 [75].  “Gatekeeper” genes directly regulate the growth of cells 
and  “caretaker ” gene are the genes controlling cell proliferation and cell apotosis  directly.  
 
Caretaker pathway  
 
Caretaker genes are the genes controlling cell proliferation and cell apotosis indirectly. 
Therefore, in the pathway initiated by mutations in caretaker genes, neoplasia occurs indirectly.  
Inactivation of caretakers leads to genetic instability that results in an elevated mutation rate of 
all genes, including gatekeeper genes [75, 77]. Accumulation of genetic alterations in other 
genes that directly control cell apoptosis or cell death will further promote tumor progression. 
Known caretaker genes include mismatch repair (MMR) genes which cause HNPCC [78]. 
 
Hence in HNPCC, patients have inherited a mutant allele of a caretaker (MMR) gene. Then a 
subsequent somatic mutation of the normal allele inactivates the MMR system in the cell. When 
the cell accumulates mutations of the MMR genes and other growth controlling genes, tumor 
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formation is promoted. MMR inactivation causes the infidelity of replication of repeated 
sequences (microsatellites) in tumor, microsatellite instability (MSI) is the first hallmark of the 
HNPCC. The HNPCC tumors also arise from adenomatous polyps (but very few or even without 
polyps), based on the tumorigenesis model, these polyps contain K-ras mutation and 
“gatekeeper” gene mutation, e.g APC mutations[79]. But several target gene like TGFβRII , 
IGFIIR , PTEN, BLM , TCF-4,Bax  have been found somatically affected in gastrointestinal 
tumors [80-82].  
Gatekeeper Pathway  
Gatekeepers are the genes that directly regulate the growth of tumors by inhibiting cell growth or 
promoting cell death. It is assumed that each cell type has only one or a few gatekeepers [79].   
In the majority of CRC, the Wnt-involved APC gene serves as the gatekeeper gene. It is one of 
early and frequently mutated genes in CRC [83]. Inactivation of APC gene will cause 
unbalanced cell growth, i.e., the cell birth rate is over that of cell death, and then the tumors 
begin to grow [75]. 
 
 
Figure 1.3: Pathways that control colorectal tumorigenesis. Mutations in the APC/β-catenin 
pathway initiate the neoplastic process through microscopic aberrant crypt foci, resulting in small benign 
tumors (adenomas). As these tumors progress, mutations in other growth-controlling pathway genes (such 
as K-Ras, B-Raf, PI3K, or p53) accumulate and adenomas become carcinomas, which eventually 
metastasize. The process is accelerated by mutations in caretaker genes [72].  
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Based on the adenoma-carcinoma tumorigenesis model (Figure 1. 3), oncogene mutations (e.g, 
K-ras and C-myc) are often required for tumor progression after the APC mutation. In general 
50% of all colon cancers show K-ras mutations at the early stages of tumor progression. Their 
mutation frequency decreased during progress [84]. 
When adenoma formation is initiated by APC gene, it is promoted to grow faster to a large 
adenoma. Other tumor suppressor genes like SMAD2/SMAD4 and DCC (deleted in colon 
cancer) start to be involved in the progress. DCC was lost in 50% of late adenomas and 
carcinomas but not in intermediate adenomas[85]. Studies have shown that inactivation of 
SMAD4 gene resulted in more malignant adenomas with extensive stromal proliferation and 
invasive growth [85]. DCC gene and SMAD2/SMAD4 are all located on chromosome 18. Thus, 
loss of activity of one or more genes on Chr18 does appear to be an important step in tumor 
development.  
 
 
 
Figure 1.3: Model of genetic alteration in the development of colorectal cancer  [74,76] 
  
When finally a P53 mutation (on chromosome 17q) occurs, the balance on cellular proliferation 
and apoptosis is lost due to the failure of cellular apoptosis.  At this point, it is assumed cells 
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accumulated all the genetic alterations and the adenoma progresses to carcinoma accompanied 
by chromosome instability and aneuploidy [86]. 
In colorectal cancer, FAP and 85% of sporadic CRCs followed this pathway [87]. Both FAP and 
sporadic carcinogenesis accumulate mutations by the "adenoma-carcinoma sequence" [88]. 
 
The tumorigenesis model and pathways discussed above are believed to contain the backbone of 
genetic alteration in the majority of sporadic CRCs.   
“Two- hit” hypothesis in colorectal cancers 
Nonetheless, gatekeepers and caretakers are all tumor suppressor genes in both pathways. The 
tumor suppressor genes followed Knudson’s “two-hit” hypothesis to initiate the tumor growth. 
In hereditary cancers, tumor suppressor genes (TSG) carry a germline mutation, so it usually 
only requires a second somatic mutation for tumorigenesis, while in non-hereditary cancer 
(sporadic cancers), two somatic mutations need to be in the same somatic cell to inactive TSG in 
order to initiate tumor formation[89]. (Figure 1. 4)  
This hypothesis was first developed for retinoblastoma tumors. Later it was found that most 
dominantly inherited cancers followed this hypothesis. Studies have been shown that this second 
somatic event may arise by a variety of molecular mechanisms, for example new intragenic 
mutations, gene deletions, chromosomal loss or somatic recombination [89, 90].  
It was understandable that people who inherit an inactivated copy of a tumor suppressor gene 
had a higher risk of developing the associated form(s) of cancer than people born with two 
normal copies, as postulated in two-hit model. Indeed, it was shown that in the tumors of these 
predisposed patients, the remaining wild-type copy of the tumor suppressor gene was lost, a 
process referred to as loss of heterozygosity (LOH) [90]. LOH leads to either deletion of the 
tumor suppressor locus or “reduction to homozygosity” (two alleles occur to be identical without 
net loss of genetic material) [91, 92]. Later studies confirmed that this concept is also suitable 
for other tumor suppressor genes.  
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Figure 1.4: Knudson’s two-hit hypothesis for tumorigenesis involving a tumor suppressor gene 
(TSG) One pair of chromosomes is depicted, with one TSG (the normal gene (grey), the mutated gene 
(yellow star), and deletion of the gene (absence) are shown. (a) In familial cancer, Individuals inherited a 
germline mutation of the TSG as first ‘hit’ in every cell and require only one subsequent ‘hit’ in a cell to 
initiate a cancer (b) Normal individuals have two normal copies of the TSG, so two independent ‘hits’ 
(mutations) are required in the same somatic cell to initiate a cancer [90]. 
 
In FAP syndrome, in agreement with Knudson’s “two-hit” hypothesis, inactivation of both APC 
alleles can be detected in most intestinal tumors at early stages of tumor development [93]. 
However, detailed mutation analysis of tumors from patients with FAP and APC min mice has 
shown an interesting result:  The position and type of the second hit in FAP polyps depends on 
the localization of the APC germline mutation. This is claimed in a two-hit model, in which any 
LOH mutation would result in tumor formation. It showed that the dependence between germline 
mutation and the resulting spectrum of somatic mutations that successfully lead to tumor 
formation is more complex than suggested previously. Most of time the somatic mutation and 
germline mutation are linked to the multi-function region of the APC gene. This multifunction 
region contains three 15-amino-acid repeats and seven 20-amino-acid repeats (AAR). which act 
as the binding domain of ß-catenin and are crucial for downregulating ß-catenin [94-96]. Somatic 
mutation analysis of polyps from different FAP patients also showed how APC is inactivated and 
starts tumor formation in association with the activation of ß-catenin signaling rather than at the 
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complete loss of regulatory function of APC within this signaling pathway. This is called the “just 
right” model [91]  . Therefore, in FAP the somatic mutation of APC depends on its germline 
defect. Additional specific subset of somatic mutations will successfully lead to tumor formation 
in the colon and rectum [97] .  
Compared to the good understanding of the APC gene in FAP patients, little is known about the 
second hit and the molecular mechanisms of the malignant tumor initiation and progression in 
HNPCC with MMR gene mutations. In large, the ability of defective MMR genes to cause 
HNPCC appears to follow the “second hit” hypothesis, in which germline mutations confer 
predisposition but need a second hit for tumor initiation.  
Generally, heterozygous mutants of mismatch repair genes are still mismatch repair proficient 
[98-100]. However, when the wild type allele of the gene is also lost through somatic events 
(second hit), the tumor will progress[101]. This leads to replication errors (RER) in the short 
repeat sequence, that is why we believe microsatellite instability is caused by the somatic 
inactivation of the corresponding second mismatch repair allele (“second hit”) [46]. There are 
several mechanisms possibly responsible for the inactivation of the mismatch repair genes, e.g, 
point mutations, allelic losses as well as epigenetic processes such as aberrant methylation of 
cytosine and guanine rich promoter regions (CpG islands). Previous reports have shown that LOH 
is frequently found in tumors from HNPCC patients with germline MMR mutations [102].  But in 
2001, Kruse etal have shown that in Muir-Torre syndrome which is caused by MSH2 germline 
mutation, loss of heterozygosity is not the preferred model of somatic inactivation of the second 
MSH2 allele. Therefore, it remains unclear which somatic inactivation mechanisms account for 
tumor initiation in patients with known MMR germline mutations.  
 
1.4 Aims of this thesis 
In this thesis, we investigated the frequence and nature of large genomic rearrangements in 
MMR mutation negative patients (Chapter3.1), the prevalence of germline mutations of MYH 
inAPC mutation negative polyposis patients (Chapter 4.2). Subsequently, we did a detailed 
investigation of the in somatic alterations in cancers from HNPCC and AFAP patients to 
characterize the second hit and third hits (Chapter 3.2, Chapter 3.3, Chapter 4.1) in order to 
understand the mechanism of the tumor initiation and progression in colorectal cancer. 
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CHAPTER 2 
2. Methods 
2.1 DNA extraction 
DNA extraction from peripheral blood  
Genomic DNA was isolated from EDTA blood applying the salting-out procedure described by 
Miller et al (103). Briefly, 10 ml of blood were mixed with 30 ml of EL buffer (155mM NH4Cl, 
10 mM KHCO3, 1 mM EDTA, pH 7.4) and left on ice for 15 minutes. The lysate was 
centrifuged at 2000 rpm for 10 minutes, washed twice with EL buffer and the intact leukocyte 
pellet resuspended in NL buffer (10 mM Tris-HCl, pH 8.2, 400 mM NaCl, 2 mM Na2EDTA, 1% 
SDS and 200µg/ml proteinase K) and incubated overnight at 37ºC. The next day, 1 ml of 6M 
NaCl was added and vigorously shaken followed by centrifugation to remove cellular proteins. 
The supernatant containing the DNA was placed in a fresh tube and the DNA precipitated with 
ethanol. The resulting DNA pellet was washed with 70% ethanol, dried briefly, and then 
suspended in 1 ml of TE buffer (10 mM Tris.HCl, pH 7.5, 0.1 M EDTA) for over night until all 
the pellet dissolved(103) . 
DNA extraction from paraffin-embedded formalin-fixed tissue 
After histopathological classification of hematoxylin/eosin-stained, formalin-fixed tissue blocks, 
a representative portion of the tumor (adenoma or carcinoma) with an average tumor contents of 
> 70% was scraped off and DNA extraction performed according to the Qiaamp tissue kit’ 
protocol (QIAGEN,Basel, Switzerland). Briefly, 180µl of buffer ATL and 20µl proteinase K (20 
ng/ µl) were added to each tumor sample, which then were incubated overnight at 55ºC for 
digestion, until the tissue was completely lysed. Next day, 200µl of buffer AL were added and 
incubated at 70ºC for 10 min, followed by the addition of 210µl of ethanol (100%) and mixed 
thoroughly by vortexing. Then mixture was transferred into Qiaamp spin column and 
centrifuged at 10’000 rpm for 5 min. After having discarded the filtrate, 250µl of washing buffer 
AW were added 2 times and centrifuged at full speed (14’000 rpm). Finally, the DNA was 
eluted twice with 50µl -200µl of buffer AE.  
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Quantitation of genomic DNA 
Measure DNA concentration by Eppendor Biophotometer (Eppendorf AG, basel, Switzerland). 
Quantify DNA by diluting 5µl DNA into 55µl distilled water (1:12 dilution). An absorbance of 1 
unit 260nm corresponds to 50µg DNA/µl.   
2.2 RNA extraction 
Total RNA was isolated by Qiagen RNeasy Mini Kit from Heparin blood of patients according to 
the protocol supplied by the manufacturer (QIAGEN, Basel, Switzerland). Collect blood cells 
(not over maximum 1x107) by centrifugation in 350µl RLT buffer (lysis buffer), disrupt and 
homogenize the samples to break down genomic DNA and reduce viscosity of the lysate. After 
centrifuged Lysate for 3 min at 14000rpm, supernatant is transferred to the 350 µl 70% ethanol. 
700 µl of sample was applied to an RNase mini spin column. The column was centrifuged at 
maximum speed. 700RW1 buffer is added to the RNeasy column, in cubate column for 5 
minutes, and centrifuge it. RPE buffer 500 was added to RNeasy column following, and also 
centrifuge at maximum speed to wash the membrane.  30ul DEPC (RNase free) water was added 
as elution buffer into column, samples were collected by centrifuging it  for 5min at maximum 
speed.  
Quantitation of total RNA 
Measure DNA concentration by Eppendor Biophotometer (Eppendorf AG, basel, Switzerland). 
Quantify RNA by diluting 5 µl RNA in 55 µl DEPC water (1:12 dilution). An absorbance of 1 
unit at 260nm corresponds to 40µg RNA/ml. 
 
2.3 Microsatellite Marker Analysis  
Microsatellite Marker analysis of HNPCC tumors 
For MSI analysis, genomic DNA and tumor DNA were investigated using a panel of 
microsatellite markers. 11 microsatellite markers were applied for analysis. They are located at 
different chromosome corresponding to different genes (MSH2, MSH6, MLH1,c-kit ,3-beta-
HSD,APC). They are Marker DS123, D2S2227, D2s2369 and BAT 26; D3s1597, D3s3611, 
D3s3594 and D3s 3601; BAT 25; BAT 40 and D5S346. All these markers shared similar PCR 
amplification process. Within PCR amplification, 50-100ng of genomic DNA and tumor DNA 
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were mixed with 15µl true allele mix (Applied Biosystems, Rotkreuz, Switzerland), PCR 
reaction is performed on Eppendorf Mastercycle machine(Eppendorf AG, basel, Switzerland ). 
The PCR program was initiated by 94°C 12 minute to active hot-start Tag polymerase and 
denature the template, followed by 10 cycles at 94°C 15 seconds, annealing (detail see appendix 
1) 15 seconds, 72°C 30 seconds, another 20 cycles were performed at 89°C 15seconds, 
annealing 15 seconds , 72°C 15 seconds, with final cycle at 72°C, 6 min. Primer sequences, 
product length and the labeling dye of these primers are shown in table 1 of appendix 1. 
Subsequently, 2 µl of PCR products mixed with 18 µl deionized formamide (Applied 
Biosystems, Rotkreuz, Switzerland), 0.5 µl ROX500 size standard was added and the mixture 
was loaded onto an ABI PRISM 310 sequencing machine using the POP4 polymer (PE Applied 
Biosystems, USA). Analysis was performed by Genescan software and Genotyper 2.5 software. 
MSI was determined with respect to the number of microsatellite markers displaying allelic 
expansions or contractions. The interpretation of the presence of MSI, defined as the occurrence 
of novel alleles, followed the NCI workshop’s recommendations (59): MSS: all the markers are 
stable; MSI-Low: >0- <30% markers are unstable; MSI-high: >30% of markers are unstable. 
Tumor samples from HNPCC patients were included as positive controls. Loss of heterozygosity 
(LOH) was defined as a >50% reduction in relative intensity of one allele compared to the other 
(104, 105). 
 
Loss of heterozygosity analysis of the APC gene and MMR genes 
In the case of germline nonsense mutations and large deletion in APC and MMR genes, loss of 
heterozygosity (LOH, allelic loss) analysis was performed using microsatellite markers: D5S346, 
D5S299 and D5S82 , D5S318,MBC, DS123, D2S2227 ,D2S2369, D3S1597, D3S3594, D3S 3601 
(see primer sequence in appendix 1), which map on the location of these genes. In the case of 
germline (and somatic) frameshift mutations, LOH analysis was performed using oligonucleotide 
primers which encompassed the germline insertion/deletion, which was then used to access allelic 
loss. Standard methods of fluorescence-based genotyping on the ABI310 sequencer were used. 
Allelic loss was scored at any informative marker if the area under one allelic peak in the tumor 
was reduced by more than 50% relative to the other allele, after correction for the relative peak 
areas of the alleles found in constitutional DNA of the same patient. 
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2.4 Immunohistochemistry (IHC) 
After MSI analysis, all tumors with MSI were analyzed by immunohistochemistry (IHC) 
experiment in Zurich (Dr. Giancarlo Marra, the Institute of Molecular Cancer Research, University 
of Zurich, Switzerland). Four micrometer serial sections from paraffin blocks were mounted on 
silanized slides, deparaffinized and rehydrated. Antigen retrieval was obtained by heating the 
sections in a pressure cooker at 120°C for 2 min in 10mM citrated-buffered solution (pH 6.0). 
DAKO peroxidase blocking reagent and goat serum were sequencially used to suppress 
nonspecific staining due to endogenous peroxidase activity and nonspecific binding of antibodies, 
respectively. Incubations with primary monoclonal antibodies were performed as follows: 
antiMSH2: 24 hours at 4C with Ab NA26 (Oncogene Research), 1μg/ml; antiMSH6:2 hours at RT 
with Ab G70220 (Transduction Laboratories), 4μg/ml; anti MLH1: 1 hour at RT with Ab 13271A 
(PharMingen), 1.2 μg/ml; anti-hPMS2: 24 hours at 4C with Ab 65861A (PharMingen), 3 μg/ml. 
After washing, anti-mouse secondary antibodies conjugated to peroxidase labelled polymer 
(DAKO EnVision+kit) were applied for 30 min at RT, and the peroxidase activity was developed 
by incubation with 3.3‚ diaminobenzidine (DAB) chromogen solution (DAKO). Sections were 
then counterstained slightly with hematoxylin.  
2.5 Denaturing High Performance Liquid Chromatography (dHPLC)  
The dHPLC method was developed primarily as pre-screening method in the identification of 
sequence variations in a number of disease genes (106, 107). dHPLC is based on the detection of 
heteroduplexes in short segments of DNA by ion-reversed phase high performance liquid 
chromatography (108, 109).Partial heat denaturation within an acetonitrile gradient leads to the 
separation of the DNA strands, resulting in the formation of hybrid wild type/mutant 
heteroduplexes. These heteroduplexes have a reduced column retention time and hence an altered 
mobility compared to their homoduplex counterpart. The big advantages of the dHPLC method 
include low cost, the use of automated instrumentation and the speed of the analysis (2.4 minutes 
to 5 minutes per sample). This technique has been successfully employed in the detection of 
mutations and polymorphisms in the Y chromosome, exons from the factor IX and 
neurofibromatosis type 1 genes10, rearranged transforming (RET), cystic fibrosis transmembrane 
conductance regulator (CFTR) and phosphatase and tensin homologue on chromosome (PTEN) 
genes (108) , BRCA1 and BRCA2 (110) and MLH1 and MSH2 (111). 
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Figure 2.1: Outline of dHPLC method (109).  
 
 Screening of Mutation Cluster Region (MCR) of APC gene by dHPLC  
The APC protein contains 2,843 residues with several structural motifs. The mutation cluster 
region is the region that encompass from codon 1250 to codon 1560. It contains two of the most 
commonly found pathogenic mutations, 5-bp deletions creating stop codons at positions 1061 and 
1309. This region hosts three Armadillo repeats (15– and 20–amino acid repeats). The 20 amino 
acid repeats are important for APC mediatie β-catenin degradation (112). 
 DNA samples were amplified for mutations in the tumor DNA of APC attenuated mutation carrier 
by PCR based methods. Because the difficulties of tumor DNA amplification, we designed 12 
primers to cover the whole MCR region with short PCR products. The final products were applied 
on the highly sensitive WAVE 3500HT dHPLC (Transgenomic, Crewe, UK). Melting 
temperatures for dHPLC were predicted by the Wavemaker software version 4.1.42 
(Transgenomic). The different elution profiles were observed, in comparison to control samples 
(negative control samples and positive control samples) run in parallel. 12 different PCR products 
of APC MCR region were denatured by different melting temperature (see appendix 2). This 
method was also applied for MYH mutation analysis, see melting temperature of different exons of 
MYH in appendix 2.  
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2.6 Direct DNA Sequencing 
After IHC screening or dHPLC screening, direct sequencing was applied to screen entire coding 
region of all the suspective MMR gene. DNA sequencing was also applied for the sample, which 
showed different patterns in dHPLC screening of APC MCR region and MYH coding region. PCR 
products were purified using the QIAquick PCR Purification kit (Qiagen, Basel, Switzerland). The 
sequencing reaction was performed using the Big Dye Teminator Cycle Sequencing kit (Applied 
Biosystems, Rotkreuz, Switzerland), according to the manufacturers' guidelines. Following 
purification using the DyeEx 2.0 Spin Kit (Qiagen, Basel, Switzerland) sequencing products were 
analysed on an ABI PRISM 310 Sequencing machine (Applied Biosystems, Rotkreuz, 
Switzerland). All the mutations identified in all genes were confirmed by sequencing in both, 
forward and reverse directions, and from at least 2 independent PCR products. Appendix 1 showed 
all the primers applied for the directly DNA seqeuencing.  
2.7 Quantitive Multiplex PCR Ampilification (QMPA) detection  
To amplify all 16 exons of MSH2 and all 19 exons of MLH1, we motified the primer pairs and 
PCR conditions according to reference (113). Primers length and sequence are descriped in 
appendix 1. All the upstream primers were labeled with the fluorescent dye 6-FAM at their 5’end. 
Seven groups of multiplex PCR reactions were performed. Each group contained six pairs of 
primers encompassing both genes (Table 2. 1). Some primer pairs were present in two or more 
multiplex reactions as controls. The final volume of each multiplex PCR was 12.5 µl, containing 
50ng of template DNA, 10 pmol of each pair of primers, dNTPs (final concentration 0.2 mM) and 
0.25µl units Taq DNA polymerase (Invitrogen, Karlsruhe, Germany). Because of the different 
annealing temperatures of the primers, we performed PCR in two steps: the first step comprised 10 
cycles starting with an annealing temperature corresponding to the highest Tm value of the primer 
set followed by a decrease of 1ºC/cycle.The second step comprised 10 cycles at a constant 
annealing temperature equal to the lowest Tm value of this primer set (detailed information in 
Table 2. 1). PCR was performed on Eppendorf Mastercycle PCR machine (Eppendorf AG, Basel, 
switzerland). Then 2µl PCR products were mixed with 18µl of deionized formamide plus 0.5µl 
ROX500 size standard. The mixture was analyzed on ABI 310 DNA Sequencer machine with 
POP4 polymer. (Applied Biosystems, Rotkreuz, Switzerland). 
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Table 2.1. Primer concentration and annealing temperature of QMPA 
Group  MSH2  MLH1  Annealing  Cycles 
  volume of primer  µl (50pm / µl)  
volume of primer 
 µl (50pm / µl)  temperature   
Group 1 exon3 (0.15+0.15)    exon 8 (0.15+0.15)     
  exon5 (0.1+0.1)   59°C in cycle 1 12(cycles ) 
  exon9 (0.15+0.15)   51°C in cycle 2 12(cycles ) 
  exon13 (0.2+0.2)       
  exon16 (0.15+0.15)       
Group 2 exon 2 (0.3+0.3) exon 1 (0.05+0.05)     
  exon 15 (0.1+0.1) exon 8 (0.075+0.075) 58°C in cycle 1 12(cycles ) 
    exon 10 (0.1+0.1) 51°C in cycle 2 12(cycles ) 
    exon 16 (0.1+0.1)     
  exon 6 (0.3+0.3) exon 5 (0.15+0.15)     
Group 3   exon 6 (0.2+0.2) 55°C in cylce 1 12(cycles ) 
    exon 10 (0.2+0.2) 51°C in cycle 2 12(cycles ) 
    exon 18 (0.2+0.2)     
    exon 19 (0.15+0.15)     
Group 4 exon 3 (0.15+0.15) exon 3 (0.2+0.2)     
  exon 14 (0.15+0.15) exon 4 (0.15+0.15) 57°C in cycle1 12(cycles ) 
    exon 11 (0.15+0.15) 51°C in cycle 2 12(cycles ) 
    exon 12 (0.1+0.1)     
  exon 1 (0.2+0.2) exon 2 (0.1+0.1) 55°C in cycle1 12(cycles ) 
Group 5 exon 10 (0.2+0.2) exon 7 (0.05+0.05) 51°C in cycle2 12(cycles ) 
  exon 14 (0.15+0.15) exon 14 (0.05+0.05)     
  exon 2 (0.2+0.2) exon 7 (0.1+0.1)     
Group 6 exon 4 (0.2+0.2) exon 13 (0.15+0.15) 58°C in cylce1 12(cycles ) 
  exon 7 (0.15+0.15)  52°C in cycle 2 12(cycles ) 
  exon 12 (0.2+0.2)       
Group 7 exon 8 (0.2+0.2) exon 2 (0.2+0.2)    
  exon 11 (0.2+0.2) exon 9 (0.1+0.1) 56°C in cylce1 12(cycles ) 
    exon 15 (0.2+0.2) 51°C in cycle2 12(cycles ) 
    exon 17 (0.1+0.1)     
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Detection of Genomic Deletions 
Detection of genomic deletion was based on the comparison of the peak areas of different exons 
amplified in a multiplex PCR. All the samples were analyzed by Genescan software and the Peak 
areas were calculated by Genotyper software 2.5 (Applied Biosystems) and exported to an excel 
spread sheet. For evaluation of the different exons of a multiplex PCR group, one peak was taken 
as a reference (Pr), the other five peaks as intended peaks (Pi). In a first step the ratio between 
peak areas (Pi/Pr) was evaluated. To calculate the copy number, the ratio Pi/Pr was further divided 
by the ratio of the same exons obtained in negative control samples (Ci/Cr). A value around 1.0 of 
the (Pi/Pr) /(Ci/Cr) ratio was regarded as absence of deletion; a value reduced to 0.5 was 
interpreted as a heterozygous deletion of the intended exon. Since experimental conditions do not 
allow differentiation of deletions from duplications when one of the two genes is entirely involved, 
an additional multiplex PCR that also amplifies fragments from a third gene was performed in 
such cases (see example in chapter 3.1). 
2.8 Multiplex ligation-dependent probe amplification (MLPA) detection 
For the detection of aberrant copy numbers in the MLH1 and MSH2 genes in constitutional 
(leukocyte-derived and tumor DNA), the SALSA P003 MLH1 / MSH2 test MLPA kit (MRC 
Holland, Amsterdam, The Netherlands) was used (114).The kit contains probes for the 16 exons of 
MSH2 and the 19 exons of MLH1 as well as 7 probes located on different chromosomes as 
controls. DNA samples from 2 known germline deletion carriers (MLH1 exon1_10del; MSH2 
exon8_15del) as well as from 10 healthy probands were used to confirm the sensitivity and 
specificity of the method. Each mutation was confirmed on a second, independently drawn blood 
sample from the respective patient. 
The MLPA reaction contains three steps to complete the reaction: Probe hybridization, Ligation and 
PCR amplification. All the reactions were performed on Eppendorf Mastercycle PCR machine 
(Eppendorf AG, Basel, switzerland).PCR products were analyzed on ABI PRISM310 sequencing 
machine in POP 4 polymer with 47 cm capillary. (See detail in Appendix III) 
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Figure 2.2: Outline of the MLPA method (114). 
Statistic Analysis of MLPA products  
Fragment analysis was performed on an ABI PRISM 310 sequencing machine with POP4 
polymer. The results were analysed using the Genescan and Genotyper software (Applied 
Biosystems, Rotkreuz, Switzerland) to identify the specific peak representing the respective exons 
and control loci. Peak areas and heights were then exported to a Microsoft Excel spreadsheet and 
calculations performed according to the method described by Taylor et al.; 
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http://leedsdna.info/science/dosage/REX-MLPA/REX-MLPA.htm). Fragments with high standard 
deviation (>15%) were omitted from further analysis. An average dosage ratio close to 1 is 
expected for individuals with two copies, whereas values close to 0.5 indicate loss of one copy. In 
tumor-derived DNA samples, inevitably containing some degree of contaminating normal tissue, 
values of <0.3 implied loss of both copies. 
 MLPA results, which indicated a germline or a somatic deletion were independently confirmed in 
at least one additional, independent experiment as well as independently drawn blood samples if 
available. All apparently single exon deletions were screened by direct DNA sequencing to 
exclude sequence variations within the ligation-probe binding site which can mimic single exon 
deletions (115, 116). 
2.9 Long Range PCR 
Long-Range PCR on genomic DNA was used to confirm the deletions uncovered by multiplex 
PCR with the Expand High Fidelity PCR System (Roche, Diagnostics GbmH, Mannheim, 
Germany). Primers located in intron 6 and intron 9 of MLH1 (see mutiplex PCR primer appendix 
1) were applied. PCR was performed according to the manufacturers recommendations with some 
small modifications: samples were denaturated at 95°C for 5 min followed by 10 cycles of 
denaturation at 95°C for 45 sec, annealing/extension at 62°C for 10 min, then 30 cycles of 
denaturation at 95°C for 45 sec, annealing at 55°C for 50 sec and extension at 68°C for 10 min, 
and a final extension at 68°C for 15 min.  PCR products were separated on a 1% agarose gel and 
visualized by ethidium bromide staining.  
2.10 RT-PCR  
cDNA amplification 
cDNA was amplified by using Qiagene One Step RT-PCR  kit. 
About 50ng to 3mg of total RNA were reverse transcribed into complementary DNA with 5 µl 10 
x RT-PCR buffer(1x buffer: 10mM/L Tris, 50mM/L KCl, and 0.2mg/ml BAS, pH 8.5), 5 µl of 
10mMdNTP mix (5mM each dNTP) and 2ul random primer (10 µM), 10 units RNA inhibitor, 3 µl 
Reverse Transcriptase 600U/ µl. The procedure was completed by heating the samples for 2 hours 
at 37°C. Polymerase chain reaction (PCR) amplifications were performed in 50 µl total volumes 
on an Eppendorf Mastercycle (Eppendorf AG, Basel, Switzerland ).  
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2.11 Protein Truncation Test (PTT) 
After cDNA synthesis, PCR amplifications were performed in 50 µl total volumes as following:  
100ng cDNA, 0.2U Taq (Gibco/PWO, Gibco USA/Boehringer Mannheim, USA), 2.5 µM each 
dNTP, 5mM MgCl2, 10x reaction buffer (1x buffer: 10mM/L Tris, 50mM/L KCl, and 0.2mg/ml 
BAS, pH 8.5) and 0.5 µM of each primer. PTT primer sequences for MLH1, MSH2 were carefully 
designed (see appendix 1), and used to amplify each gene into two overlapping segments of 
different size . The cycling conditions were as follows: 94°C-4 min. for 1 cycle, 94°C-45 secs ,  
55°C /55°C/56°C-1 min. (for MSH2, APC and MLH1, respectively), and 72°C-3 mins for 45 
cycles, and 72°C-10 mins for 1 cycle on Eppendorf Mastercycle (Eppendorf AG, basel, 
Switzerland ).  
PCR products were first evaluated on a 1% agarose gel. Subsequently, the PTT was run by adding 
4 µl PCR product to 6 µl PTT Mix (200 µl TNT T7 coupled Reticulocyte Lysate System,  8 µl 
RNasin, 16 µl TNT reaction buffer, 16 µl S35 Methionine) and heating for 60 minuates at 30°C. 
The reaction was stopped with 10 µl of 1x sodium dodecyl sulfate (SDS) sample buffer. 
Subsequently, the products were loaded onto a 12% SDS polyacrylamide gel and run for 110 
minuatess at 35 mA. The gels were then fixed (10% glacial acetic acid, 30% methanol) for one 
hour and dried for 45 minutes at 80°C before exposure on a Biomax film (Kodak, Rochester, NY).  
Results were analyzed and compared to healthy control in parallel.  
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without Pre-existing Polyposis :  
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CHAPTER 3.1 
3.1 Evaluation of different screening techniques to detect large genomic 
rearrangements in MSH2 and MLH1 
 
3.1.1 Abstract  
Large genomic rearrangements in the mismatch repair genes MSH2 and MLH1 are estimated to 
account for up to 27% of all mutations in patients with hereditary nonpolyposis colorectal cancer 
(HNPCC). Since large genomic deletions are missed by direct DNA sequencing, two novel 
methods were recently introduced to overcome this limitation: i) the semi-quantitative multiplex 
PCR assay (QMPA), ii) the multiplex ligation dependent probe amplification (MLPA) assay. 
Whereas the first method divides all 35 exons of MSH2 and MLH1 into 7 separate groups for 
PCR multiplexing, MLPA amplifies up to 45 sequences simultaneously. 
We tested both methods on 35 Swiss patients clinically suspected of HNPCC, in whom no 
germline mutation could be identified by direct DNA sequencing. Twenty-one of them presented 
with microsatellite instability in their cancers, 17 of which showed immunohistochemical loss of 
either MSH2 or MLH1. 
Both QMPA assay and MLPA readily identified the deletions in the control samples.  Novel 
MLH1 germline deletions spanning exons 7 to 9 as well as a novel MSH2 deletion encompassing 
exons 7 and 8 were detected by both methods. The mutations were found to segregate with 
disease and were further characterized by RT-PCR and long-range PCR. An additional MSH2 
deletion detected by QMPA could not be confirmed by other methods. 
 In conclusion, we have identified two novel large genomic deletions in MSH2 and MLH1. Four 
deletion carriers were identififed by QMPA, and three of them could be confirmed by MLPA. 
Both methods, QMPA and MLPA, appear to be of comparable sensitivity albeit with different 
specificity. 
3.1.2 Introduction 
Hereditary nonpolyposis colorectal cancer is an inherited cancer syndrome caused by mutations 
in mismatch repair genes (1, 2), with the majority of mutations being detected in MLH1 and 
MSH2 (3-5). Somatic inactivation of the remaining copy leads to cancer development. Several 
kinds of germline mutations have been detected in HNPCC, including truncating, frameshift, 
splicing or missense mutations (mutation database, www.hgmd.org). The presence of many 
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deletions and other rearrangements in these genes can not be detected by common mutation 
screening methods,  e.g. heteroduplex analysis, denaturing gradient gel electrophoresis (DGGE), 
single strand conformational analysis (SSCP), and direct DNA sequencing (6, 7). Alternatively 
the Protein Truncation Test (PTT) and cDNA amplification are methods able to identify 
intragenic exon spanning deletions. However, due to alternatively spliced sites and nonsense 
mediated decay, large deletions could be missed by both techniques (8). In addition, mRNA 
material is not always available for investigation. Southern blot has been the gold standard to 
demonstrate genomic deletions in MSH2 were much more prevalent than previously thought (9), 
but this method requires large amounts of DNA (10µg). To fill this detection gap, several PCR 
based gene dosage measurement techniques have been developed recently. With these methods 
large DNA rearrangements were detected in several cancer predisposition genes at a frequency of 
around 4-15% (10, 11).  
Large germline deletions within the mismatch repair genes MSH2 and MLH1 account for a 
significant proportion (up to 27%) of all deleterious mutations of these genes which are associated 
with HNPCC syndrome (12, 13). The QMPA method is a simple and reliable means of screening 
for such alterations (14). With this method, several PCR reactions cover the 35 exons of MLH1 
and MSH2. We have modified the primers and PCR conditions for this multiplex PCR protocol, 
compared to those previously published. The method is based on semi-quantitative PCR of all the 
exons. Thus, a deletion of one gene can reliably be detected by using exons of the other gene as a 
reference. Two large deletions in MSH2 and two large deletions in the MLH1 gene could be 
detected by this method. These results were confirmed by other methods including MLPA 
(Multiplex Ligation-Dependent Probe Amplification). MLPA is a new and high-resolution 
method for detecting copy number variation in genomic sequences (15). It has been reported to be 
a robust assay, and offers several advantages over existing techniques by existing reports (16). 
Many diagnostic genetics laboratories are therefore adopting this as a routine method for gene 
dosage analysis of genes such as BRCA1, BRCA2, and the mismatch repair genes in preference 
to other techniques.  
There is a clear clinical need for simple and reliable means of screening for these rearrangements. 
Importantly, for each new molecular re-arrangement thus detected, it is desirable to devise a 
simple PCR based diagnostic method to search for the mutation in family members at risk . We 
therefore evaluated the two methods for quantitative analysis, which could complement routine 
screening for mutations of MMR genes. 
Our aim was to compare these two techniques QMPA and MLPA, in terms of their sensitivity and 
specificity to detect copy number variations.  
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For this we screened genomic DNA of 35 mutation negative HNPCC patients by QMPA and 
MLPA. We identified 4 deletions by QMPA, three of which were confirmed by MLPA. In 
addition,we were able to determine the breakpoint in one of the deletion carriers. 
 
3.1.3 Patients and Methods 
Patients  
A total of 35 Swiss patients with clinically diagnosed HNPCC were screened for germline 
mutations in the MLH1 and MSH2 genes. No germline mutations were detected in any of these 
patients by direct DNA sequencing. (Table 3.1. 1) 
The diagnostic criteria applied were the Amsterdam Criteria I and the Bethesda Guidelines. 
Twenty-one patients showed microsatellite instability in their CRCS. Seventeen of which 
showed also immunohistochemical loss of either MSH2 or MLH1. The mean age of CRC 
diagnosis was 47 years. The tumor status was MSI-high in 17 patients, and MSI–low in 4 
patients. Two positive controls with known genomic deletions status (contributed by the Human 
Genetics research group from the University of Bonn, Germany) were used to validate the 
techniques. DNA of 10 healthy individuals was used as negative controls.   
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Table 3.1.1: Clinical and molecular features of the 35 MLH1/MSH2 mutation-negative 
HNPCC patients investigated for genomic rearrangements.  
 
Family Age at diagnose IHC gene MSI Criteria Sex 
1676 43 MLH1 MSI-Low ACI f 
1806 61 MLH1 MSI-High ACI m 
1739 69 MLH1 MSI-High none f 
1754 48 MLH1 MSI-Low AC I m 
1781 53 MLH1 MSI-High AC I f 
1806 61 MLH1 MSI-High AC I m 
1739 76 MLH1 MSI-High No criteria f 
2055 36 MLH1 MSI-Low BG f 
2068 70 MLH1 MSI-High none f 
2064 83 MLH1 MSI-High none m 
1671 55 MSH2 MSI-High No criteria m 
1750 51 MSH2 MSI-High ACI m 
1835 63 MSH2 MSI-High ACI f 
1804 35 MSH2 MSI-High ACI m 
1833 36 MSH2 MSI-High ACI m 
1942 39 MSH2 MSI-High BG m 
2081 43 MSH2 MSI-High BG m 
1672 49 nd MSI-Stable AC I m 
1645 48 nd MSI-Stable No criteria m 
1692 33 nd MSI-Low AC I m 
1703 54 nd MSI-Stable AC I f 
1716 26 nd MSI-Stable BG m 
1722 38 nd MSI-Stable BG f 
1776 35 nd MSI-High BG f 
1809 35 nd MSI-Stable BG f 
1815 39 nd MSI-Stable AC I m 
1817 38 nd MSI-Stable AC I m 
1826 74 nd MSI-Stable AC I f 
1831 79 nd MSI-Stable AC I m 
1844 39 nd MSI-Stable BG m 
1865 33 nd MSI-Stable BG f 
1857 31 nd MSI-High AC I f 
1885 44 nd MSI-High AC I f 
1895 19 nd MSI-Stable BG f 
1903 33 nd MSI-Stable BG f 
Abbreviations: CRC denotes colorectal cancer; MSI: microsatellite instability;IHC, 
immunohistochemically assessed loss of expression of respective protein; ACI, Amsterdam criteria I; BG, 
Bethesda guidelines. f: female; m: male; nd=not determined 
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Methods  
DNA extraction: See Chapter 2 general methods 2.1  
QMPA:  See Chapter 2 general methods 2.7        
Primers: See appendix I 
Detection of Genomic Deletions: See Chapter 2 general methods 2.7 
MLPA: See Chapter 2 general methods 2.8  
RT-PCR: See Chapter 2 general methods 2.10  
Long Range PCR: See Chapter 2 general methods 2.9 
3.1.5 Results 
With QMPA, the 16 exons of MSH2 and the 19 exons of MLH1 were amplified simultaneously in 
seven multiplex PCR reaction groups followed by fragement analysis on an ABI 310 genetic 
analyzer. Chromatograms were generated and peak heights and areas evaluated by Genotyper 2.5 
software (Applied Biosystems) for each multiplex PCR group. Although there is a good 
correlation between peak height and peak areas, the peak area proved to be the more reliable 
parameter for calculations. 
Validation of the QMPA 
Before screening the patients, we tested the reproducibility of the assay with DNA samples from 
10 healthy controls and from 2 patients with known exon deletions in MLH1 and MSH2 in five 
consecutive experiments. Finally, the ratios between peaks areas of five different exons compared 
to that of several reference exons were calculated.   
In Table 3.1.2, we present an example of the validation tests: The relative ratios obtained from 10 
healthy controls displayed a similar standard deviation (SD) of <15%, and were comparable to 
SD values obtained from patients DNA samples. The known deletions of exons 1-10 in MLH1 
gene (deletion control 1) and exons 8-15 in MSH2 (deletion control 2) were reproducibly detected 
by this assay (Table 3.1. 3). 
Quantification detection of QMPA 
The detection of genomic deletions was based on the comparison of on the peak areas of different 
exons simultaneously amplified in a multiplex PCR from healthy controls and patients. Peak 
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areas were obtained by Genotyper Analysis software 2.5 and exported to an excel sheet. Methods 
for calculation: within one reaction group which contains six exons from the MLH1 or MSH2 
gene, one peak from a control exon (The exons were chosen from either MLH1 or MSH2) was 
taken as a reference (Pr), then the other five peaks were taken as intended peaks (Pi) to obtain the 
Pi/Pr value.The 10 healthy control samples were calculated in the same manner to get Ci/Cr ratio. 
The ratio Pi/Pr was further divided by the ratio obtained from the control samples Ci/Cr. If the 
value (Pi/Pr)/(Ci/Cr) equals 1.0, this means absence of a deletion; a value of around 0.5 was 
interpreted as a heterozygous deletion of the intended exon. If the value was 2 to 2.5, this 
indicated a deletion in the reference exon or duplication in the intended exon (Table 3.1. 3). 
Base on this calculation rules, patient 1817 and 1835 showed deletion in MSH2 exon8 
(reference). Patient 1806 showed a deletion in MLH1 exon 9 (see Table 3.1. 3). Standard 
deviations of the experiments were fewer than 15%.  
 
Table 3.1.2:  Relative Ratios of QMPA products (Pi/Pr) from different exons in ten healthy controls 
 
 
Control 
No. 
MLH1 
ex 17 
MLH1 
ex 9 
MLH1 
ex 15 
MLH1 
ex 2 
MSH2 
ex 11 
MSH2 
ex 8 
1 0.86 0.62 0.82 1.16 0.95 1 
2 0.69 0.48 0.71 1.06 1.04 1 
3 0.77 0.55 0.8 1.15 1.04 1 
4 0.69 0.69 0.73 1.07 1.07 1 
5 0.7 0.66 0.73 0.95 1.05 1 
6 0.94 0.79 0.88 0.99 0.94 1 
7 0.79 0.48 0.78 0.98 0.99 1 
8 0.8 0.73 0.82 0.99 1.03 1 
9 0.85 0.74 0.82 1.13 0.96 1 
10 0.82 1.01 0.94 1.06 0.95 1 
mean± 0.79 0.67 0.8 1.05 1.01 1 
SD 0.08 0.11 0.07 0.07 0.05 0 
SD% 10.37 12.78 8.71 7.06 4.63 0 
 
*Ratio is calculated from Ci/Cr (intended peak area/reference peak area), in this group, MSH2 is 
taken as internal reference.  
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Table 3.1.3: Deletion analysis example for MLH1 exon 9 by QMPA in 23 patients  
Patient ID. MLH1 exon9 (Pi) MSH2 exon8 (Pr) (PiPr)/(Ci/Cr) Intepretation  
Deletion control 1 23478 38277 0.32 Deletion in Pi 
Deletion control 2 48354 12257 2.03 Deletion in Pr 
1676 49226 19924 1.03  
1692 18626 9889 0.97  
1739 45882 22247 1.06  
1750 44868 20677 1.12  
1781 40553 17255 1.21  
1804 48213 21552 1.15  
1806 25277 29698 0.44 Deletion in Pi 
1817 45086 9327 2.49 Deletion in Pr 
1833 42263 19551 1.11  
1835 40053 10873 1.9 Deletion in Pr 
1857 44714 18398 1.25  
1885 47481 20908 1.17  
1942 56410 27501 1.06  
1934 46809 19223 1.25  
1971 40907 17468 1.21  
2068 45314 24565 0.95  
1957 47391 20720 1.18  
2079 42356 17590 1.24  
2055 36582 18886 1  
2064 48805 20215 1.24  
2065 45314 24565 0.76  
2081 47391 20720 1.24   
2227 42356 17590 1.05   
Control 
 mean value                 50566(Ci) 26050(Cr)      Ci/Cr=0.944  
*Peak area was given by Genotyper 2.5 software; Pi and Pr, intended or reference peak areas in patients 
(internal reference is MSH exon8 peak areas); Ci and Cr, intended or reference peak areas in control. 
Deletion control 1 carries MLH1 exon1 to 10 deletions. Deletion Control 2 carries a MSH2 exon8 to 15 
deletions. 
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Results of deletion screening in 35 patients  
As an example, Figure 3.1. 1 shows a deletion detected by QMPA, Table 3.1. 4 shows calculation 
of relative copy number. After QMPA screening, four large deletions were identified:  Two 
patients (patient 1817 and patients 1835) having MSH2 exons 7 and 8 deleted. MLH1 exons 7 and 
9 were deleted in patient 1806 , patient 1676 carries an MLH1 exon 13 deletion.  
 
 
 
A 
B 
 
 
Figure 3.1. 1: Peak patterns of QMPA PCR products (A panel: control samples, B panel: patient 1806). 
These patterns were generated using primers of three different multiplex groups. Comparing control vs. 
patient, peak area ratios for exons 7, 8 and 9 of MLH1 were calculated. (Table 3.1.3) 
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Table 3.1.4: Relative Values of QMPA products (PiPr/CiCr) from MLH1 exons 1-11 
 Deletion control 1 carries a deletion of  MLH1exons 1 to 10  
   1806/1 and 1806/2 are two affected family members from family 1806 
   Controls 1 to 10 are healthy control subjects. Values below 0.5 indicated exonic deletions.  
Patient 
ID exon1 exon2 exon3 exon4 exon5 exon6 exon7 exon8 exon9 exon10 exon11 
Deletion 
Control 1 0.53 0.48 0.56 0.48 0.49 0.41 0.39 0.38 0.46 0.39 0.78 
1806/01 1.06 0.95 1.15 0.97 1.09 0.99 0.51 0.47 0.49 1.21 1.06 
1806/02 1 0.96 1.14 0.96 1.05 1.07 0.5 0.46 0.47 1.11 0.88 
Control 1 0.99 1.01 0.99 0.97 0.96 0.97 0.99 0.96 0.92 0.91 0.97 
Control 2 1.44 1.47 1.13 1 1.21 1.33 1.12 1.23 1.27 1.49 1.46 
Control 3 0.92 0.93 1.05 0.92 0.98 0.98 1.03 0.97 0.9 0.95 1.04 
Control 4 1.01 0.97 1.09 1.02 0.94 0.97 0.95 0.9 0.88 0.83 0.86 
Control 5 1.1 1.03 1 1.04 0.86 0.93 0.92 0.8 0.76 0.77 0.93 
Control 6 1.03 1.03 0.94 1.1 0.87 0.93 0.99 0.88 0.89 0.71 0.91 
Control 7 1.01 1.02 1.04 0.99 0.98 1.02 1.01 1 0.96 0.94 1.01 
Control 8 0.97 0.96 1.02 1.01 0.96 0.98 0.99 0.97 0.95 0.91 0.98 
Control 9 0.92 0.93 0.89 1.01 1.09 0.96 1 1.09 1.21 1.17 1.03 
Control10 0.98 0.96 0.96 1.02 0.95 0.95 0.95 0.92 0.96 0.9 0.98 
 
Confirmation of the deletions  
cDNA confirmation  
The deletion of exons 7 to 9 in the MLH1 gene was successfully confirmed by cDNA 
amplification (Figure 3.1. 2). The sequencing result for patient 1806 cDNA showed the precise 
breakpoint location at MLH1 codon 454 (exon 5) and codon 884 (exon11). Due to alternative 
spliced sites in MLH1 exon 6, exon 9 and exon 10 (18), exons 7 and 9 to 10 were spliced out in 
healthy control; in patient 1806, the break point was found to be located at the end of exon 5 
(Figure 3.1. 2) and the start of exon 11. The breakpoint identification of MSH2 exon7_8 deletion 
patients could not be assessed,   because no patients mRNA was available for analysis.  
 
35 
 Chapter 3.1   
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MLH1 exon11 
 
Figure 3.1.2: Determination of deletion breakpoints in patient 1806  
A: cDNA amplification (MLH1 exon 5 to 11) of healthy controls and affected members from family 1806. 
Because of alternative splicing of exons 6 and exons 9-10, the amplification products are smaller  than  
expected (660bp). Note the 250 bp fragment only present in affected members from family 1806. B: 
Compared to the healthy negative control sample displaying the direct transition from exon 8 to 11 (exons -
6, 9 and 10 are spliced out), patient 1806-1, having deleted exons 7 to 9, shows joining of exon 5 to 11. 
 
Long Range PCR confirmation 
Long Range PCR was also applied to confirm the deletion of MLH1 exons 7 to 9 from genomic 
DNA. The patients who carry the novel MLH1 deeltion (exon7_9 del) showed a 10kb PCR 
product (Figure 3.1. 3). The products were amplified by primers located at MLH1 exon 6, and 
downstream primer located at MLH1 exon 10. The presence of a 7.8 kb product suggests the 
products with presence of the exon7 to 9 deletions.  
Long range PCR could not performed to confirm the deltion of MSH2 exon7_8 deletion because 
MSH2 exons 7 and 8 host very large intronic sequence (13kb and 15kb).  
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A Figure 3.1.3: Confimation of deletion by 
Long Range PCR from genomic DNA 
A: arrow indicate PCR products without 
deletion. 
B: arrow indicate PCR products generated 
by exon deletion of MLH1 exon7 to exon9  
 
A 
 
MLPA  
We also applied the MLPA method to re-screen all patients.  The MLPA assay proved robust and 
more reliable regarding peak area distribution (Figure 3.1. 4) compared to QMPA and lower 
standard deviations (Table 3.1. 5). Changing the size standard profile in GENESCAN software 
allowed us to align the amplification patterns of controls and patients for direct comparision 
(Figure 3.1. 4). Genotyper 2.5 software was applied to obtain the peak area values of the 
chromatogram. The MLPA method was first evaluated by screening ten healthy controls with 
standard deviations (SD) below 0.15. 
The result of the MLPA was confirmed in three of the deletion carriers. Patient 1817 whose 
MSH2 exon 7 to 8 deletion was detected by QMPA showed no deletion in MSH2 by MLPA. 
(Table 3.1. 5)  
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Table 3.1.5: Gene dosage analysis by MLPA: Typical dosage result showing a deletion of MLH1 
exon7 to exon9 in patient 1806.But in patient 1817, there is no deletion found in MSH2 exon7 to exon 
8. 
 
Patient 1817      Patient 1806     
Ave Ave 
Category DR SD  Category DR SD 
con 10p11 1.07 0.11  con 10p11 0.89 0.13 
con 10p14 0.91 0.1  con 10p14 1.27 0.11 
con 17q21 1.09 0.05  con 17q21 1.02 0.14 
con11p12 0.81 0.13  con11p12 0.99 0.14 
con11p13 0.98 0.08  con11p13 0.88 0.13 
con.5q31 1.32 0.09  con.5q31 0.85 0.12 
con4q25 1.03 0.12  con4q25 1.12 0.09 
MSH2 ex5 1.17 0.11  MLH1.EX5 0.98 0.14 
MSH2 ex6 1.13 0.14  MLH1.EX6 0.99 0.14 
MSH2 ex7 1.19 0.06  MLH1.EX7 0.55 0.08 
MSH2 ex8 1.01 0.11  MLH1.EX8 0.51 0.07 
MSH2 ex09 1.45 0.09  MLH1.EX9 0.46 0.07 
MSH2 ex10 1 0.1  MLH1.EX10 1.15 0.12 
MSH2 ex11 0.97 0.15  MLH1.EX11 0.91 0.13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*The average Dosage Ratio (DR) is the mean of the dosage ratio. This dosage ratio is calculated like: Peak 
area (each exon fragment)/Peak area (control fragment). Values close to 1 are expected for individuals with 
two copies of the test fragment and close to 0.5 for individuals with loss of one copy.   
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Figure 3.1.4: Peak profile of MLPA products, Red peaks indicated patient, Blue peaks indicated healthy 
control, A: Patient 1817 and healthy control comparison pattern, B: Patient 1806 and healthy control 
comparison pattern. Peak area calculation is showed in Table 3.1. 5.  
3.1.5 Discussion  
With mutation detection methods such as heteroduplex analysis, DGGE, SSCP, or dHPLC (6), it 
is not possible to uncover large exon deletions at the level of genomic DNA. Southern blot is the 
gold standard to detect large genomic deletions in DNA mismatch repair genes (9). But as a 
routine application, this method is time consuming and also requires large amounts of DNA. All 
of these disadvantages limit its value in a routine diagnostic setting. Other methods like RNA 
based sequencing and PTT are able to detect intragenic deletions (8).  Large deletions however 
might extend over the location of the primers used in RT- PCR and will therefore fail to yield a 
PCR product. So deletion of an entire gene can hardly be detected by this method. Another 
disadvantage of RNA based methods is that large deletions can also be missed due to alternative 
splicing (8). Recently two different multiplex PCR assays have been introduced, they are QMPA 
and MLPA (19). Here we have compared sensitivity and specificity of these methods in detecting 
large genomic deletions in MLH1 and MSH2 gene. 
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The detection of genomic deletions by QMPA, requires three principles to be followed in order to 
get reliable results: 1) PCR reactions must be performed within the period of the exponential 
amplification. The quantification correlates with the quantity of DNA template copies. 2) The 
primers for different exons of MLH1 and MSH2 within the same group should be reliably 
amplified.  3) Each multiplex PCR reaction has seven different primers with different melting 
temperatures (Tm). In order to get efficient annealing temperatures, each primer concentration 
has to be well optimized to balance the individual primer specific PCR efficiency. As a rule of 
thumb: The higher the Tm values of primers, the lower the concentration of the respective primer 
pair.  
It is important however, to take the following consideration into account. The group of primers 
working in the same QMPA has to be designed carefully to avoid interference between primers. 
The QMPA assay presented here is characterized by stability and sensitivity. It can be applied for 
simultaneous detection of genomic deletions in both MSH2 and MLH1 genes. In the case of 
rearrangements involving the entire MSH2 or MLH1 gene, an additional internal control of 
another gene has to be used in order to differentiate between deletion or duplication of one of 
these two genes.  
Because primer concentrations have to be modified within the same group to balance QMPA  
efficiency, other conventional methods after QMPA screening must be applied to confirm the 
results in order to  avoid the false positive and negative results.  
MLPA has gained growing reputation in genetic diagnostic laboratories due to its simplicity, 
relative low cost, low DNA consumtion, capacity for reasonably high throughput and robustness 
(20). With the MLPA, we were able to amplify products covering all 35 exons of MLH1 and 
MSH2 together plus additional seven chromosomal controls in one single PCR. Chromosomal 
controls have been well selected as internal controls to evaluate every amplification. They located 
at different chromosomes in addition to the chromosomes on which MLH1/MSH2 are located.  
The MLPA reaction relies on the probe to hybridize to the exact and unique location of the 
respective exonic sequence. The hybridization sites of MLH1 and MSH2 MLPA kit are carefully 
picked to avoid a possible polymorphisms iin these two genes. Because they all share the same 
universal PCR primers, the primer concentrations do not have to be modified in the MLPA assay.  
Using the MLPA assay, we were able to confirm the two deletions in the MLH1 and the one in 
MSH2. One deletion was false-positive by QMPA, but due to unavailability of mRNA and 
technical reasons (>30kb intronic sequence), we could not do further investigation for this. 
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 In conclusion, both methods, QMPA and MLPA can readily identify the deletions in the deletion 
control samples, albeit with variable specificity. The QMPA technique, however is difficult to set 
and standardize the PCR conditions in order to obtain reproducible results. The MLPA method, in 
contrast, proved easy to use (one step amplification) and gave fast and highly reproducible 
results.  
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CHAPTER 3.2 
3.2 Gene Conversion Is a Frequent Mechanism of Inactivation of the Wild-Type 
Allele in Cancers from MLH1/MSH2 Deletion Carriers 
Zhang J, Lindroos A, Ollila S, Russell A, Marra G, Mueller H, Peltomaki P, Plasilova M, 
Heinimann K. (Cancer Res 2006; (66)2: 659-64) 
3.2.1 Abstract 
Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominantly inherited cancer 
predisposition syndrome caused by germline mutations in DNA mismatchrepair genes, 
predominantly MLH1 and MSH2, with large genomic rearrangements accounting for 5 to 20% of 
all mutations. Although crucial to the understanding of cancer initiation, little is known about the 
second, somatic hit in HNPCC tumorigenesis, commonly referred to as loss of heterozygosity 
(LOH). Here we applied a recently developed method,  multiplex ligation dependent probe 
amplification (MLPA), to study MLH1/MSH2 copy number changes in 16 unrelated Swiss 
HNPCC patients, whose cancers displayed microsatellite instability and loss of MLH1 or MSH2 
expression, but in whom no germline mutation could be detected by conventional screening. The 
aims of the study were i) to determine the proportion of large genomic rearrangements among 
Swiss MLH1/MSH2 mutation carriers and ii) to investigate the frequency and nature of LOH as 
second, somatic event in tumors from MLH1/MSH2 germline deletion carriers. Large genomic 
deletions were found to account for 4.3% and 10.7% of MLH1 and MSH2 mutations, respectively. 
MLPA analysis of 18 cancer specimens from two independent sets of Swiss and Finnish 
MLH1/MSH2 deletion carriers revealed that somatic mutations identical to the ones in the 
germline occur frequently in colorectal cancers (6/11; 55%) and are also present in extracolonic 
HNPCC-associated tumors. Chromosome-specific marker analysis implies that loss of the wild-
type allele predominantly occurs through locus-restricted recombinational events, i.e. gene 
conversion, rather than mitotic recombination or deletion of the respective gene locus. 
 
3.2.2 Introduction 
Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominantly inherited cancer 
predisposition syndrome characterized by the occurrence of early onset colorectal carcinoma 
(CRC) as well as a defined spectrum of extracolonic tumors, such as cancers of the endometrium 
and renal pelvis (1). HNPCC is caused by germline mutations in DNA mismatch repair (MMR) 
genes, predominantly MLH1 and MSH2, with 5 to 20% of mutations being large genomic 
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rearrangements missed by conventional mutation screening techniques (2-4). Recently, the 
multiplex ligation dependent probe amplification (MLPA) method has been introduced to assess 
DNA copy number changes semiquantitatively (5).  This method requires considerably less DNA 
(50 to 200 ng) than conventional Southern blotting (5 to 10 μg) and the short recognition 
sequence of the probes moreover allows to determine copy number changes in partially degraded 
DNA, such as DNA from formalin-fixed cancer tissue. According to Knudson’s “two-hit” 
hypothesis a second, somatic mutation, inactivating the wild-type allele and commonly referred to 
as loss of heterozygosity (LOH), is required for tumorigenesis to start (6). Subsequent mismatch 
repair deficiency leads to accumulation of replication errors, mainly at short repetitive DNA 
sequences, in the tumor cell and gives rise to the molecular hallmark of HNPCC, microsatellite 
instability (MSI).  Although crucial to the understanding of cancer initiation, only scarce data are 
available on the nature of the second hit in HNPCC tumors (7). Here we applied the MLPA 
technique on 16 unrelated Swiss HNPCC patients, whose cancers displayed MSI and loss of 
MLH1 or MSH2 expression, but in whom no germline mutation could be detected by 
conventional DNA sequence. The study aimed i) to determine the proportion of large 
genomicrearrangements in our set of Swiss MLH1/MSH2 mutation carriers and ii) to investigate 
the frequency and nature of LOH as second, somatic event in HNPCC tumorigenesis in cancers 
from MLH1/MSH2 germline deletion carriers. 
 
3.2.3 Patients and Methods 
Sixteen unrelated Swiss patients referred to the division of Medical Genetics because of clinically 
suspected HNPCC syndrome were included in this study. The cancers from these patients had 
been found to display microsatellite instability and loss of MLH1 or MSH2 expression (Table 3.2. 
1). Since no pathogenic germline mutation could be detected in MLH1 or MSH2 by conventional 
DNA sequencing, all patients were investigated for the presence of large genomic rearrangements 
in their germline. Subsequently, the presence/absence of the identified MLH1/MSH2 germline 
deletion was assessed in 11 cancers as well as in 7 cancers from known Finnish germline deletion 
carriers (8, 9). Written informed consent was obtained from all patients included in the study. 
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Table 3.2.1: Clinical and molecular features of the 16 MLH1/MSH2 mutation-
negative HNPC patients investigated for genomic rearrangements. CRC denotes 
colorectal cancer; MSI: microsatellite instability; IHC: immunohistochemical protein 
loss; f: female; m: male; ACI: Amsterdam Criteria I; BG: Bethesda guidelines. 
 
Patient 
ID 
Sex Age at 
diagnosis 
Criteria CRC site MSI IHC Exon(s) deleted 
1676/1 f 43 ACI Sigmoid MSI-Low MLH1 exon 13 
1806/1 m 61 ACI Transverse MSI-High MLH1 exon 7 to 9 
2055/1 f 36 BG Sigmoid MSI-Low MLH1 no deletion detected 
2079/1 m 65 BG Caecum MSI-Low MLH1 no deletion detected 
2065/1 m 68 none Transverse MSI-High MLH1 no deletion detected 
1739/1 f 69 none Transverse MSI-High MLH1 no deletion detected 
2068/1 f 70 none Sigmoid MSI-High MLH1 no deletion detected 
2064/1 m 83 none Ascendens MSI-High MLH1 no deletion detected 
2264/1 f 39 ACI Ascendens MSI-High MSH2 exon 8 to 16 
2227/1 m 59 BG Caecum MSI-High MSH2 exon 8 to 11 
1835/1 f 63 ACI Descendens MSI-High MSH2 exon 7 to 8 
1804/1 m 35 ACI Transverse MSI-High MSH2 no deletion detected 
1833/1 m 36 ACI Caecum MSI-High MSH2 no deletion detected 
1942/1 m 39 BG Sigmoid MSI-High MSH2 no deletion detected 
2081/1 m 43 BG Ascendens MSI-High MSH2 no deletion detected 
1750/1 m 51 ACI Ascendens MSI-High MSH2 no deletion detected 
Abbreviations: CRC denotes colorectal cancer; MSI: microsatellite instability;IHC, 
immunohistochemically assessed loss of expression of respective protein; ACI, Amsterdam criteria I; BG, 
Bethesda guidelines. f: female; m: male; 
DNA extraction from peripheral blood and tumor tissue. 
DNA from peripheral blood was isolated by using a salting-out procedure described by Miller et 
al. (10). Prior to DNA extraction from tumor tissue, histopathologic classification of H&E 
stained, formalin-fixed tissue blocks was carried out and a, representative portion of the tumor 
with an average tumor content of 70% was scraped off. DNA extraction was done according to 
the QIAamp tissue kit protocol (Qiagen, Basel, Switzerland).  
Analysis of MSI and MMR protein expression. 
 Based on the recommendations of the National Cancer Institute workshop on MSI, a panel of 
five microsatellite loci (BAT25, BAT26, D5S346, D17S250, and D2S123) was used to assess 
MSI (11). The presence or absence of four MMR proteins (MLH1, MSH2, MSH6, and PMS2) in 
the tumor was examined by standard immunohistochemical techniques (12).  
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Analysis of LOH. 
 LOH, also referred to as "allelic loss", was investigated using the following flanking 
polymorphic microsatellite markers: D3S1304, D3S1263, D3S2338, D3S1266, D3S1277, 
D3S1300, D3S1566, and D3S1278 for the MLH1 locus; and D2S168, D2S165, D2S367, 
D2S391, D2S337, D2S2110, D2S286, D2S2333, and D2S347 for the MSH2 locus. LOH was 
scored at any informative marker if the area under one allelic peak in the tumor was reduced by 
>50% relative to the other allele, after correcting for the relative peak areas in leukocyte-derived 
constitutional DNA (13). PCR conditions for LOH analysis are available from the authors upon 
request. PCR products were analyzed on an ABI PRISM 310 Genetic Analyzer (Applied 
Biosystems, Rotkreuz, Switzerland).  
MLPA  
For the detection of aberrant copy numbers in the MLH1 and MSH2 genes in constitutional, 
leukocyte-derived, and tumor DNA, the SALSA P003 MLH1/MSH2 test MLPA kit (MRC 
Holland, Amsterdam, the Netherlands) was used (5). The kit contains probes for the 16 exons of 
MSH2 and the 19 exons of MLH1 as well as seven probes located on different chromosomes as 
controls. DNA samples from two known germ line deletion carriers (MLH1 exon1_10del and 
MSH2 exon8_15del) as well as from 10 healthy probands were used to confirm the sensitivity and 
specificity of the method. Each mutation was confirmed on a second, independently drawn, blood 
sample from the respective patients. All reactions were carried out according to the 
manufacturer's protocol. Fragment analysis was done on an ABI 310 capillary sequencer and 
results were analyzed using the Genescan and Genotyper software (Applied Biosystems) to 
identify the specific amplicons representing the respective exons and control loci. Peak areas and 
heights were then exported to a Microsoft Excel spreadsheet and calculations were done 
according to the method described by Taylor et al. (14). Fragments with high SD ( 20%) were 
omitted from further analysis. An average dosage quotient close to 1 is expected for individuals 
with two copies, whereas values close to 0.5 indicate loss of one copy. In tumor-derived DNA 
samples, inevitably containing some degree of contaminating normal tissue, values 0.3 implied 
loss of both copies. MLPA results indicative of a germ line or a somatic deletion were 
independently confirmed in at least one additional, independent experiment as well as 
independently drawn blood samples, and, where available, cDNA was used to assess the 
individual break points. All apparently single exon deletions were screened by direct DNA 
sequencing to exclude sequence variations within the ligation-probe binding site which can mimic 
single exon deletions (15, 16).  
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Statistical analysis. 
 Statistical comparison of patients' features, encompassing phenotypic characteristics (gender, age 
at diagnosis, etc.), and mutational status, was done using the 2 and Fisher's exact test for 
categorical variables, or Student's t test for continuous variables, with all of the probabilities 
reported as two-tailed P values, considering P < 0.05 to be statistically significant.  
3.3.4 Results and Discussion 
In this study 16 unrelated Swiss HNPCC patients without identified pathogenic germline 
mutation in MLH1 or MSH2 were screened for the presence of large genomic rearrangements 
using the MLPA assay (Table 3.2. 1 and Figure 3.2. 1, Figure 3.2. 2 ,Figure 3.2. 3). Three (38%) 
out of 8 index patients whose colorectal cancers (CRC) showed high microsatellite instability 
(MSI) and loss of the MSH2 protein were found to harbour 3 different genomic deletions in 
MSH2.  Among the 8 index patients whose tumours had lost MLH1 expression, 2 (25%) were 
found to carry large genomic rearrangements in the MLH1 gene. In view of the late age at 
diagnosis (>68 years) as well as an inconspicuous family history in 4 of the MLH1 mutation 
negative patients, it is likely that these cancers are actually sporadic in origin, due to 
hypermethylation of the MLH1 promoter rather than due to an inherited germline mutation  (17). 
With mRNA available for further study, the consequence of the MLH1 deletion encompassing 
exons 7 to 9 (family 1806) could be assessed. By cDNA sequencing we found this genomic 
deletion to result in direct joining of exon 5 to exon 11 (c.454_884del) leading to a frameshift and 
a first premature stop codon 11 amino acids downstream. Taken together, large genomic deletions 
account for 10.7% (3/28) of MSH2 and for 4.3% (2/47) of MLH1 mutations in our set of 
mutation-positive Swiss HNPCC families (n=75). The remaining mutation-negative patients are 
currently under intensive study for mutations in regulatory regions and/or epimutations in these 
MMR genes. 
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Figure 3.2.1:   MLPA electropherograms of MLH1/MSH2 germline deletion carriers. 
A: healthy control proband; B: MLH1 exon7_9del (patient 1806); C: 
MLH1 exon13del (patient 1676); D: MSH2 exon8_11del (2227); E: MSH2 
exon7_8del (patient 1835); F: MSH2 exon8_16del (patient 2264); G: 
colorectal cancer from patient 2264 indicating a homozygous MSH2 
exon8_16del. Arrows denote deleted exons. 
 
 
 
 
 
In order to further substantiate the high frequency of cancers harbouring a somatic deletion 
identical to the one in the germline, 7 additional tumors (4 CRCs, 2 endometrial and1 stomach 
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cancer) from Finnish HNPCC patients carrying an MSH2 or MLH1 germline deletion were 
investigated (Table 3.2. 2b). Two out of 4 CRCs were found to carry identical,  biallelic deletions 
which were absent in the remaining cancers. Thus, although based on a arguably small number of 
cases, our findings from two independent sets of patients indicate that the occurrence of somatic 
deletions identical to the ones in the germline are a frequent event in HNPCC related colorectal 
tumorigenesis (6 out of 11 CRCs; 55%). Remarkably, 9 none of the Swiss or Finnish tumor 
specimens showed evidence for large somatic deletions encompassing the entire, respective gene 
locus. 
Overall, genomic deletion carriers were statistically significantly later diagnosed of CRC (median, 
59 years; IQR, 19.5; n = 5) compared with index patients carrying "conventional" MLH1/MSH2 
mutations (median, 40 years; IQR, 14.0; n = 70; P < 0.006). Four out of six (67%) deletion 
carriers (Table 3.2. 2) had, in addition to their CRC, developed extracolonic cancers: patient 
1806/3, an ovarian cancer at age 52; patient 1835/1, an endometrial cancer at age 61; patient 
2227/1, a urothelial carcinoma at age 60 and an astrocytoma WHO grade 3 at age 67; and patient 
2264/1, a duodenal and an endometrial cancer at age 41 and 48, respectively. Compared with 
other index mutation carriers in our HNPCC database, the frequency of extracolonic HNPCC-
associated cancers was statistically significantly increased (67% versus 20%; P < 0.03). 
 With regard to other phenotypic properties (e.g., site of CRC or tumor stage) no further 
significant differences were observed between the two groups. With one exception, i.e., family 
2227, in which HNPCC-related cancers were confined to one generation only, all genomic 
deletion carriers met the Amsterdam criteria I (Table 3.2. 1). Because the phenotypic observations 
might have an effect on counseling and management of MLH1/MSH2 germ line deletion carriers, 
it is important that these findings are confirmed on larger patient sets. 
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Table 3.2.2. Histologic, anatomic, and molecular features of 18 cancers from Swiss and Finnish 
HNPCC patients carrying large genomic deletions 
(A) Six Swiss HNPCC patients carrying large genomic deletions 
Patient 
ID 
Cancer type Cancer site MSI Gene Germ line 
deletion 
Somatic 
deletion 
adenocarcinoma transverse 
colon 
high MLH1 exons 7-9 exons 7-9 1806/1 
adenocarcinoma transverse 
colon 
high MLH1 exons 7-9 exons 7-9 
adenocarcinoma ascending 
colon 
high MLH1 exons 7-9 exons 7-9 1806/3 
adenocarcinoma right ovary high MLH1 exons 7-9 absent 
1676/1 adenocarcinoma sigmoid colon low MLH1 exon 13 absent 
adenocarcinoma descending 
colon 
high MSH2 exons 7-8 absent 1835/1 
adenocarcinoma endometrium high MSH2 exons 7-8 absent 
adenocarcinoma cecum high MSH2 exons 8-11 exon 11 
urothelial 
carcinoma 
left kidney low MSH2 exons 8-11 exon 11 
2227/1 
astrocytoma 
WHO grade 3 
frontal brain high MSH2 exons 8-11 exons 8-
11 
2264/1 adenocarcinoma* ascending 
colon 
high MSH2 exons 8-16 exons 8-
16 
(B) Seven Finnish HNPCC patients carrying large genomic deletions 
Patient 
ID 
Cancer type Cancer site MSI Gene Germ line 
deletion 
Somatic 
deletion 
       36:1 adenocarcinoma colon high MLH1 exons 1-2 exons 1-2 
4:4 adenocarcinoma stomach high MLH1 exons 3-5 absent 
4:5 Adenocarcinoma 
 
transverse 
colon 
high MLH1 exons 3-5 absent 
11:12 adenocarcinoma endometrium high MLH1 exon 16 absent 
1:39 adenocarcinoma endometrium high MLH1 exon 16 absent 
1:32 adenocarcinoma transverse 
colon 
high MLH1 exon 16 exon 16 
       76:1 adenocarcinoma sigmoid colon high MSH2 exon 8 absent 
* Tubulovillous adenoma with central adenocarcinoma. 
Adenocarcinoma of the intestinal type. 
Following the identification of the MLH1/MSH2 germ line deletion carriers, we applied 
microsatellite marker analysis and the MLPA assay to the cancer specimens of these patients to 
gain further insight into the frequency and the nature of the second, somatic mutational event, 
commonly referred to as LOH, involved in HNPCC tumorigenesis. A total of 11 formalin-fixed 
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cancers from six genomic deletion carriers (seven CRCs, one ovarian, one endometrial, one 
kidney cancer, and one astrocytoma) were available for investigation.  
 
Figure 3.2. 2. Gene dosage analysis in leukocyte- and tumor-derived DNA from MLH1/MSH2 germ line 
deletions carriers. A, healthy control (gray), patient 1806 carrying the MLH1 exon7_9del mutation (white), 
and his colorectal cancer (black). B, healthy control (gray), patient 2227 carrying a MSH2 exon8_11del 
mutation (white), his colorectal (black), urothelial (shaded), and brain cancer (light gray). C, healthy 
control (gray), patient 2264 carrying a MLH1 exon 8_16del mutation (white) and his colorectal cancer 
(black). 
As depicted in Table 3.2. 2A, MLPA analysis revealed that four (57%) out of seven CRCs, as 
well as one astrocytoma, actually harbor somatic deletions identical to the ones identified in the 
germ line (three MLH1 and two MSH2) and evidenced by an average decrease in gene dosage 
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(normalized ratio) from 0.45 (±0.09 SD; germ line) to 0.18 (±0.07 SD; tumor; Fig. 2). One 
colorectal and one urothelial carcinoma showed loss of one exon only. No copy number changes 
were detected in the remaining four tumors (two CRCs, one ovarian, and one endometrial cancer). 
In order to further substantiate the high frequency of cancers harboring a somatic deletion 
identical to the one in the germ line, seven additional tumors (four CRCs, two endometrial, and 
one stomach cancer) from Finnish HNPCC patients carrying an MSH2 or MLH1 germ line 
deletion were investigated (Table 3.2. 2B). Two out of four CRCs were found to carry identical, 
biallelic deletions which were absent in the remaining cancers . Thus, although based on an 
arguably small number of cases, our findings from two independent sets of patients indicate that 
the occurrence of somatic deletions identical to the ones in the germline is a frequent event in 
HNPCC-related colorectal tumorigenesis (6 out of 11 CRCs; 55%). Remarkably, none of the 
specimens from the Swiss or Finnish tumors showed evidence of large somatic deletions 
encompassing the entire, respective, gene locus.  
With regard to extracolonic cancers (n = 7), only one tumor, a grade 3 astrocytoma (patient 
2227/1), was found to carry an identical, biallelic deletion. Intriguingly, two other cancers (cecum 
and kidney) from this patient, with an exon 8 to 11 germ line deletion, harbored an identical 
single exon deletion (exon 11; Table 3.2. 2A). A false-positive MLPA result could be excluded by 
directly sequencing the ligation-probe binding site for exon 11. Both introns 10 and 11 of MSH2 
comprise several Alu repeats of the AluSx subfamily, which have been shown to be involved in 
genomic rearrangements of MMR genes (18).  
In order to distinguish between the possible mechanisms leading to homozygosity of the germ 
line mutation in the tumor, i.e., loss of the chromosome harboring the wild-type allele followed by 
chromosomal reduplication, mitotic recombination, or gene conversion (19), we investigated eight 
highly polymorphic short tandem repeat markers flanking the gene loci on the respective 
chromosome (chromosome 2 for MSH2, chromosome 3 for MLH1). As depicted in 
Supplementary Table 3.2. S3 (supporting online material), none of the tumors showed allelic loss 
at the markers flanking the respective gene locus. Therefore, loss of the chromosome carrying the 
wild-type allele followed by chromosomal reduplication as well as mitotic recombination per se, 
extending from the gene locus to the telomere, could be ruled out as the underlying mechanism 
responsible for loss of the wild-type allele. Hence, these findings indicate that rather a locus-
restricted event, i.e., gene conversion, has occurred in all cancers which are homozygous for the 
germ line mutation.  
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This might, at least in part, be explained by the presence of short interspersed nuclear elements, 
particularly Alu repeats, which have been shown in several studies to be involved in germ line 
MLH1/MSH2 locus rearrangements (3, 8, 18, 20). The recurrent pattern of somatic deletions 
identical to the germ line indicate that it is possible that Alu-mediated gene conversion at the 
MLH1 and MSH2 loci is frequently occurring in HNPCC-associated tumors and that it is not 
restricted to CRC only, as evidenced by our findings on kidney and brain cancer specimens. 
Moreover, inactivation of the wild-type allele by gene conversion seems to be independent of the 
type of germ line mutation.5  
If gene conversion is indeed the predominant mechanism which leads to inactivation of the wild-
type allele, the LOH frequency at the MLH1 or MSH2 loci would be expected to be low. This is 
supported by data from Kruse et al., who observed LOH in only one out of nine skin tumors from 
eight unrelated Muir-Torre patients with MSH2 mutations (7). Clearly, future studies on larger 
sets of HNPCC patients carrying MLH1/MSH2 mutations are needed to conclusively establish the 
frequency of gene conversion events in colorectal as well as extracolonic cancers. These 
investigations should also help to elucidate the mechanistic role of Alu-mediated recombination in 
the generation of the second, somatic mutation in tumors from MMR gene mutation carriers.  
In conclusion, large genomic deletions in MLH1/MSH2 were found to account for 4.3% and 
10.7% of MLH1 and MSH2 mutations, respectively, in our set of Swiss HNPCC families. 
Deletion carriers were statistically significantly later diagnosed of CRC and exhibited more 
extracolonic cancers when compared with "conventional" MLH1/MSH2 mutation carriers. 
Analysis of cancer specimens from two independent sets of Swiss and Finnish MLH1/MSH2 
deletion carriers revealed (a) that somatic deletions identical to the ones in the germ line occur 
frequently (55%) in CRCs and (b) that this type of inactivation of the wild-type allele is also 
present in extracolonic HNPCC-associated tumors. Chromosome-specific marker analysis implies 
that loss of the wild-type allele predominantly occurs through locus-restricted recombinational 
events, i.e., gene conversion, rather than mitotic recombination or deletion of the respective gene 
locus.  
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Supplementary Table 3.2. 3: Loss of heterozygosity (LOH) analysis in cancers from MSH2 (a) 
and MLH1 (b) germline deletion carriers displaying either somatic deletions identical to the ones 
in the germline or loss of a single exon only (2227/1CRC and UC). * refers to the physical 
distance from the respective gene locus; CRC:colorectal cancer, UC: urothelial cancer, AC: 
astrocytoma, MSI:microsatellite instability, na: repeatedly failed to amplify, ni: notinformative. 
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Supplementary Figure 3.2.3: MLPA GENESCAN electropherograms of Fa1806(MLH1 exon7_9 
Deletion).  
Blue: Indicated Normal control. Red: Fa 1806( MLH1 exon7_9 deletion) from constitution DNA  
Dark:colorectal cancer from patient 1806 indicating a homozygous MSH2 exon8_16del. 
Simple line denote non-deletion exons and chromosome control. Filled field denote exons that 
deleted. 
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CHAPTER  3.3 
3.3 A de novo MLH1 germline mutation in a 31 year old colorectal cancer patient 
Martina Plasilova, Jian Zhang, Roberta Okhowat, Giancarlo Marra, Markus Mettler, 
 Hansjakob Mueller and Karl Heinimann 
Genes Chromosomes Cancer. 2006 Dec;45(12):1106-10 
3.3.1 Abstract  
Hereditary non-polyposis colorectal cancer (HNPCC) is an autosomal dominantly inherited 
cancer predisposition syndrome caused by mutations in DNA mismatch repair (MMR) genes, 
predominantly MSH2 and MLH1. Here we report the first proven de novo germline mutation in 
MLH1 (c.666dupA) identified in a 31 year old colorectal cancer patient carrying the alteration in 
all three germ layers (heterozygous ) as well as in his colon cancer (homozygous). The mutation 
was absent in both biological parents and all sibs available. Despite extensive segregation 
analysis the parental origin of c.666dupA could not be conclusively determined, representing 
either a single mutational event in a parental ger cell or (maternal) gonadal mosaicism. Though 
rare, consequential application of the Bethesda guidelines for genetic testing should allow the 
clinician to readily identify colorectal cancer patients carrying de novo MMR gene mutations.  
3.3.1 Introduction  
Hereditary non-polyposis colorectal cancer (HNPCC [MIM 114500]) is an autosomal dominantly 
inherited cancer predisposition syndrome which accounts for approximately 5% of all colorectal 
cancers (1). The disease is caused by germline mutations in DNA mismatch repair (MMR) genes, 
predominantly MSH2 and MLH1. Mutation carriers develop, mainly right-sided, colorectal 
cancer (CRC) at a mean age of 43 years with CRCs typically exhibiting microsatellite instability 
(MSI) ,the molecular hallmark of MMR deficiency.  
To identify individuals with HNPCC who should be tested for MSI the Bethesda guidelines have 
been introduced (2, 3). Both, the former and the revised Bethesda guidelines allow investigating 
individuals with apparently sporadic CRC diagnosed before age 45 and 50 years, respectively. 
According to the literature, de novo germline mutations in MMR genes are exceptionally rare 
which stands in clear contrast to other hereditary CRC syndromes, such as familial adenomatous 
polyposis coli, juvenile polyposis and Peutz-Jeghers syndrome, where 25% to 29% of germline 
mutations in the respective genes are thought to have arisen de novo (4-6). Although recurrent de 
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novo mutations in MSH2 have been inferred by haplotype analysis, only one patient with a 
proven de novo germline mutation (in MSH2) has been reported to date (7, 8). Here we present 
conclusive evidence for a de novo germline mutation in the MLH1 gene.  
3.3.3 Results and Discussion  
Following colonoscopy because of blood in the stool, 31 year old male patient 2247/1 was 
diagnosed of an invasive adenocarcinoma located at the left colonic flexure (pT3, G3 pN0) and a 
left-sided hemicolectomy was performed. The detailed family history did not reveal any further 
first or second degree family member afflicted with cancer. The patient’s family originated from 
Italy and the parents, aged 52 and 57, were not related to each other. Except for the patient, all 
family members including 4 more siblings were healthy (Figure 3.3. 1). Since the patient fulfilled 
the Bethesda guidelines, DNA from formalin-fixed colorectal cancer tissue (>70% tumor contents) 
was investigated for the presence of MSI using the recommended NCI panel of microsatellite 
markers 2. All markers were found to display novel alleles, corresponding to a MSI-high status in 
the tumor. Subsequent immunohistochemical analysis for the presence of MMR proteins (MLH1, 
MSH2, PMS2, MSH6 and MSH3) in the CRC revealed concomitant loss of expression of MLH1 
and PMS2. Consequently, bi-directional DNA sequencing of the coding sequence of MLH1 
(GenBank no. NM_0000249.2; primer sequences available upon request) identified a novel 
mutation in exon 8, c.666dupA, which results in a frameshift leading to a first premature stop 
codon at position 225 (p.Ser225X; Figure 3.3. 2a). The mutant protein is expected to lack the 
MLH/PMS interaction domains 9.  
 
Except for the patient, all family members including 4 more siblings were healthy (Figure 3.3. 1). 
Since the patient fulfilled the Bethesda guidelines, DNA from formalin-fixed colorectal cancer 
tissue (>70% tumor contents) was investigated for the presence of MSI using the recommended 
NCI panel of microsatellite markers (2). All markers were found to display novel alleles, 
corresponding to a MSI-high status in the tumor. Subsequent immunohistochemical analysis for 
the presence of MMR proteins (MLH1, MSH2, PMS2, MSH6 and MSH3) in the CRC revealed 
concomitant loss of expression of MLH1 and PMS2. Following bi-directional DNA sequencing 
of the coding sequence of MLH1 (GenBank no.NM_0000249.2;) identified a novel mutation in 
exon 8, c.666insA, which results in a frameshift leading to a first premature stop codon at 
position 225 (p.Ser225X; Figure 3.3. 2a). The mutant protein is expected to lack the MLH/PMS 
interaction domains (9). 
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To confirm paternity, a panel of 9 highly polymorphic short tandem repeat markers (AmpFlSTR 
Profiler kit; Applied Biosystems, Rotkreuz, Switzerland) were assessed in the patient and his 
parents. No inconsistency between the parental and the patient’s alleles was observed and the 
segregation pattern was according to mendelian inheritance (data not shown). These results 
conclusively show that the MLH1 mutation c.666insA has indeed occurred de novo.  
Following genetic counselling of the family, the carrier status in two sisters of the patient, aged 
27 and 23 years, was determined. The c.666insA mutation t could be identified in none of them, a 
finding which was in each case confirmed on two independently drawn blood samples (data not 
shown).  
To determine on which parental chromosome the mutation had occurred, ten single nucleotide 
polymorphisms (SNPs) intragenic of MLH1 (rs9311149, rs4647215, rs4234259, rs4647250, 
rs4647260, rs1558528, rs2286939, rs655045, rs2286940 and rs2241031) as well as 7 
polymorphic microsatellite markers on chromosome 3 (D3S1597, D3S3611, D3S2338, D3S1277, 
D3S1300, D3S1566, D3S1278) were assessed in all available family members (Figure 3.3. 1). 
SNPs were informative in the father only and showed that the paternal chromosome transmitted 
to the patient was also present in one of his sisters. Marker analysis revealed that one of the 
maternal chromosomes was only present in the patient but in none of his sibs. Assuming gonadal 
mosaicism, it is therefore conceivable that the c.666insA mutation may actually have arisen on 
the maternal chromosome. 
In order to substantiate this assumption we assessed the presence of loss of heterozygosity (LOH) 
in the patient’s CRC. Since inactivation of the wild-type allele in the tumor is frequently 
associated with loss of the polymorphic marker alleles on the wild-type chromosome, 
identification of LOH at these markers could help to determine the parental chromosome carrying 
the mutation. Direct sequencing of exon 8 in the tumor DNA identified the c.666dupA mutation 
in a nearly homozygous state (Figure 3.3.s 2b and 3e). Subsequent multiplex ligation-dependent 
probe amplification (MLPA) analysis showed that both MLH1 gene copies were present in the 
tumor (data not shown). Although MSI hampered marker analysis in the cancer, no allelic loss 
was observed at any of the informative markers (D3S1277 and D3S2338), indicating that loss of 
the wild-type allele had occurred through a locus-restricted recombinational event. As the patient 
was not informative for any SNP within the MLH1 gene locus we could not further determine the 
parental chromosome harbouring the c.666dupA mutation.  
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In order to substantiate this assumption we assessed the presence of loss of heterozygosity (LOH) 
in the patient’s CRC. Since inactivation of the wild-type allele in the tumor is frequently 
associated with loss of the polymorphic marker alleles on the wild-type chromosome, 
identification of LOH at these markers could help to determine the parental chromosome carrying 
the mutation. Direct sequencing of exon 8 in the tumor DNA identified the c.666insA mutation in 
a nearly homozygous state (Figure 3.3. 2b). Subsequent multiplex ligation-dependent probe 
amplification (MLPA) analysis showed that both MLH1 gene copies were present in the tumor 
(data not shown). Although MSI hampered marker analysis in the cancer, no allelic loss was 
observed at any of the informative markers (D3S1277 and D3S2338), indicating that loss of the 
wild-type allele had occurred through a locus-restricted recombination event. As the patient was 
not informative for any SNP within the MLH1 gene locus we could not further determine the 
parental chromosome harbouring the c.666insA mutation. Since the mutation was present in 
tissues of endodermal (colorectal cancer) and mesodermal (blood leukocytes, colonic smooth 
muscle) origin, it is unlikely that the mutational event happened postzygotically leading to 
somatic mosaicism in the patient. Thus, the c.666insA mutation either represents a single 
mutational event in a parental germ cell or (maternal) gonadal mosaicism as indicated by 
segregation analysis. 
With regard to published data and for reasons unknown, the overall de novo mutation frequency 
in MLH1 and MSH2 appears to be very low. In our group of Swiss HNPCC index patients, de 
novo mutations may represent approximately 2% (1/47) of all MLH1 germline mutations 
identified. Though very rare, application of the Bethesda guidelines for genetic testing should 
nevertheless allow the clinician to identify CRC patients carrying de novo MMR gene mutations. 
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Figures 
 
 
Figure 3.3.1:  Pedigree of family 2247 depicting the individual haplotypes in patient 2247/1 
(II:1) and his first degree relatives available for microsatellite marker and SNP 
analysis.  
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Figure 3.3.2:Fragment length analysis of MLH1 exon 8 in different tissues. Sequencing 
electropherograms demonstrating the c.666dupA germ line mutation in MLH1 (*) in a 
heterozygous state in leukocyte-derived DNA (a) and in a nearlyhomozygous state in 
tumor-derived DNA (b) from patient 2247/1. Panels c and d depict the wild-type 
sequence present in leukocyte-derived DNA from the patient’s father (c) and mother 
(d)  
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Figure 3.3.3: Fragment length analysis of MLH1 exon 8 in different tissues.  
a): leukocyte-derived DNA from a healthy proband displaying only the wild-type allele 
(w); b) to e): patient 2247/1 carrying the c.666dupA mutation (m) in DNA samples 
from peripheral blood leukocytes (b), hair follicles (c), sperms (d) and colon cancer (e).  
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CHAPTER  4.1 
4.1 Disease severity and genetic pathways in attenuated familial  
                adenomatous polyposis vary greatly but depend on the site of the 
germline mutation. 
Sieber OM, Segditsas S, Knudsen AL, Zhang J, Luz J, Rowan AJ, Spain SL, Thirlwell C, Howarth 
KM, Jaeger EE, Robinson J, Volikos E, Silver A, Kelly G, Aretz S, Frayling I, Hutter P, Dunlop 
M, Guenther T, Neale K, Phillips R, Heinimann K, Tomlinson IP.               ( in collaboration with 
Molecular and Population Genetics Laboratory, Cancer Research UK, London Research Institute, 
London, UK.) 
Gut. 2006 Oct;55(10):1440-8. 
4.1.1 Abstract 
Attenuated familial adenomatous polyposis (AFAP) is associated with germline mutations in the 
5’, 3’ and exon 9 of APC. These mutations probably encode a limited amount of functional APC 
protein. Methods and Results. We found that colonic polyp number varies greatly among AFAP 
patients, but members of the same family tended to have more similar disease severity. 5’-
mutants generally had more polyps than the other patients. We analysed somatic APC 
mutations/LOH in 235 tumours from 35 patients (16 families) with a variety of AFAP-associated 
germline mutations. Like two previous studies of individual kindreds, we found bi-allelic changes 
(‘third hits’) in some polyps. We found that the ‘third hit’ probably initiated tumorigenesis. 
Somatic mutation spectra were similar in 5’- and 3’-mutant patients, often resembling classical 
FAP. In exon 9-mutants, by contrast, ‘third hits’ were more common. Most ‘third hits’ left three 
20-amino acid repeats (20AARs) on the germline mutant APC allele, with LOH (or proximal 
somatic mutation) of the wild-type allele;  but some polyps had loss of the germline mutant, with 
mutation leaving one 20AAR on the wild-type allele. Conclusions. We propose that mutations, 
such as nt4661insA, that leave three 20AARs are preferentially selected in cis with some AFAP 
mutations, because the residual protein function is near-optimal for tumorigenesis. Not all AFAP 
polyps appear to need ‘three hits’, however. AFAP is phenotypically and genetically 
heterogeneous. In addition to effects of different germline mutations, modifier genes may be 
acting on the AFAP phenotype, perhaps influencing the quantity of functional protein produced 
by the germline mutant allele. 
4.1.2 Introduction 
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Classical familial adenomatous polyposis (FAP) is caused by germline mutations in the 
adenomatous polyposis coli (APC) gene between codons 178 and 1580. FAP patients typically 
develop hundreds to thousands of adenomatous polyps in the colon and rectum by the third 
decade of life. If left untreated, one or more adenomas progress to carcinoma by 45 years of age. 
Extra-colonic features, such as polyps of the upper gastrointestinal tract, desmoid tumours and 
osteomas, are also common. Attenuated FAP (AFAP or AAPC)  patients generally present with a 
lower number (<100) of colorectal adenomas by their fourth decade and have a later age of onset 
of colorectal cancer (mean age 55 years) (1-3). In some AFAP patients, extra-colonic features 
have been reported to be infrequent ((4)),although other AFAP patients – such as those with 
hereditary desmoid disease – have severe extra-colonic disease (5, 6). AFAP is associated with 
germline mutations in specific regions of the APC gene (Figure 4.1. 1): the 5’-end (codons 1-177, 
exons 1-4); the 3’-end (distal to codon 1580); and the alternatively spliced region of exon 9 
(codons 311-408) (3, 7, 8). The molecular mechanism(s) underlying these genotype-phenotype 
associations for AP remains largely unknown. 
 
APC is a tumour suppressor gene and almost all mutations truncate the protein or take the form of 
allelic loss (loss of heterozygosity, LOH). Several genetic studies of colorectal adenomas from 
FAP patients have shown that somatic APC mutations are dependent on the position of the 
germline APC mutation (Figure 4.1. 1) (9-11). The APC protein contains seven 20-amino acid 
repeats (20AARs) which are involved in degrading the transcriptional cofactor beta-catenin and 
hence negatively regulate Wnt signalling. In colorectal polyps, germline mutations between 
codons 1285 and 1378 leave only one 20AAR intact and are strongly associated with somatic loss 
of the wild-type APC allele. LOH usually occurs through mitotic recombination, thus leaving two 
identical alleles and a total of two 20AARs in the tumour cell (12). FAP patients who carry 
germline mutations before codon 1285 (no 20AARs) tend to have somatic mutations which leave 
one or, more commonly, two 20AARs in the protein. Finally, patients with germline mutations 
after codon 1398 (two or three 20AARs) tend to have somatic mutations before codon 1285. The 
same associations are also found in sporadic colorectal tumours (13). This interdependence of  
‘first’ and ‘second hits’ shows that selective constraints on APC mutations are active and that an 
optimum level of beta-catenin mediated signalling must be achieved for the tumour cell to grow 
(10). There is no reason to expect that AFAP polyps are not subject to the same selection for 
optimal Wnt signalling as other colorectal adenomas. 
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The ‘first hit-second hit’ associations can explain why FAP patients with germline APC 
mutations between codons 1285 and 1378 have particularly severe colorectal disease, because the 
associated allelic loss occurs at a higher spontaneous frequency than the somatic truncating 
mutations selected in other FAP patients (9). Conversely, the milder disease in AFAP patients 
may be explained if the mutations required to give the polyp cell a strong selective advantage are 
difficult to acquire. Spirio et al (1) studied colorectal tumours from a single AFAP family with a 
germline APC mutation in the 5’-end of the gene (codon 142FS). About 12% of their polyps 
showed loss of the germline mutant allele, implying that this was a ‘third hit’ subsequent to a 
mutation on the germline wild-type allele. Furthermore, a large proportion (36%) of the 
truncating somatic mutations detected were 1bp insertions at an A6-tract between nucleotides 
4661-4666 (codons 1554-1556). Spirio et al (1) concluded that germline mutations in the 5’ 
region of APC encode proteins that retain residual activity, owing to alternative splicing or 
initiation of translation. Somatic mutations would be required not only to inactivate the wild-type 
allele, but also to reduce the residual activity of the mutant germline allele. Su et al (14) studied 9 
adenomas from an AFAP family with agermline mutation (R332X) in exon 9. They found ‘third 
hits’, including loss of the germline mutant allele and 4661insA, and showed the latter to occur on 
the germline mutant chromosome. The APC isoprotein lacking exon 9 retained at least partial 
ability to down-attenuation of the phenotype. Su et al (14) suggested that exon 9-mutant AFAP 
patients develop more tumours than the general population because the germline mutant APC 
allele could be inactivated by a broad spectrum of somatic mutations, including some, such as 
nt4661insA, that would not normally affect an wild-type APC allele. The existing studies only 
analysed single families, but established the important principle that ‘third hits’ can occur in 
AFAP. These ‘third hits’ could be LOH or mutation at codon 4661. In this study, we analysed a 
larger number of AFAP families with the following aims 
•  to search for phenotypic differences among AFAP families, both between and within 
kindreds with mutations in each of the three AFAP-associated regions of APC 
• to determine whether the two families reported were typical of AFAP 
• to find out the somatic APC mutation spectrum in AFAP patients with 3’-mutations and 
to compare this with the other AFAP-associated regions of APC 
•  to find out why 4661insA is such a common ‘third hit’ 
• to delineate the pathways of somatic APC mutation in AFAP, with emphasis on whether 
polyps end up with the optimal genotype as predicted by studies of classical FAP 
• to determine whether ‘three hits’ are always needed in AFAP. 
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Figure 4.1.1. Representation of the APC protein comprising important functional 
domains and showing regions of the protein germline mutation of which are associated 
with AFAP 
 
4.1.3 Patients and Methods 
We contacted Polyposis Registries in the United Kingdom, Switzerland, Germany and Denmark 
with a request to study colorectal tumours from AFAP patients with characterized germline APC 
mutations in the 5’- or 3’-regions of the gene (codons 1-177 and 1580-2843) or in the 
alternatively spliced region of exon 9 (codons 311-408). In total, 235 fresh-frozen or formalin-
fixed, paraffin-embedded colorectal tumours were obtained from 35 individuals in 16 families. 
All patients gave written informed consent. 231 of the tumours were colorectal adenomas, almost 
all of tubular morphology and with a median diameter of 3mm (range=1- 17mm); four tumours 
were colorectal carcinomas (median diameter=5mm, range=2-20mm). 30 tumours were from 6 
AFAP patients from 5 families with germline APC mutations in the 5’ region of the gene 
(G126X, 141FS, Q163X, 170FS, 173FS). 79 tumours were from 10 AFAP patients from 5 
families, each of which carried the relatively common R332X nonsense mutation in the 
alternatively spliced region of APC exon 9. 126 tumours were from 19 AFAP patients from 6 
families with germline APC mutations in the 3’-region of the gene (1597FS, 1738FS, 1919FS, 
1943FS, 1982FS, 2078FS). Clinical details (APC germline mutation, gender, age at presentation, 
polyp count) were obtained and are being analysed as part of a larger study of phenotype in 
AFAP (A.L.Knudsen, in preparation); numbers of polyps analysed per patient are summarised in 
Table 4.1.1. Paired normal tissue was available for all patients. H&E-stained sections were 
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prepared from each tumour to confirm the presence of at least 60% neoplastic tissue. DNA was 
extracted from tumour and normal tissue using standard methods. 
Table 4.1.1. Characteristics of 35 patients with germline APC mutations in the three 
AFAP-associated regions (5’, exon 9 and 3’; codons 1-177, 311-408 and >1580). 
FS = frameshift; n/a = not available; * from reference(8); ** from reference(10) 
 
Mutation screening 
All samples were screened for somatic APC mutations using fluorescence single strand 
conformational polymorphism (SSCP) analysis on the ABI3100 sequencer (details available 
from authors upon request). Fresh-frozen samples were screened between codons 1 and 1779. 
Owing to the limiting quantity of DNA, formalin-fixed, paraffin-embedded samples were 
screened between codons 1220 and 1603, an area encompassing the somatic mutation cluster 
region  and extending beyond the first SAMP repeat involved in axin binding.(15)Samples with 
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bandshifts on SSCP analysis were sequenced in both forward and reverse orientations from a 
new PCR product. 
Cloning 
We wished to determine the phase of somatic APC mutations with respect to the germline wild-
type or mutant allele, but the quality of DNA available from archival tumours was insufficient 
to allow long-range PCR amplification. We therefore identified a SNP (nt4479 A>G) within 
APC which was close enough to most somatic mutations of interest to be PCRamplified, and 
which was informative and linked to the disease-causing mutation. After amplification of a 
region encompassing the somatic APC mutation and the SNP, the PCR product was cloned and 
multiple clones were sequenced using the pGEM-T Easy Vector System II (Promega). 
Loss of heterozygosity analysis 
In the case of germline nonsense mutations in APC, loss of heterozygosity (LOH, allelic loss) 
analysis was performed using three microsatellite markers, D5S346, D5S421 and D5S656, which 
map close to APC. Where linkage information was available for the microsatellites studied, the 
allele targeted by the allelic loss was assigned as germline mutant or wild type. Where no linkage 
information was available, the allele targeted was determined by inspection of the sequencing 
electropherogram in constitutional and tumour DNA for the region containing the mutation. In the 
case of germline (and somatic) frameshift mutations, LOH analysis was performed using 
oligonucleotide primers which encompassed the germline insertion/deletion, which was then used 
as a pseudo-polymorphism for assessing loss. Standard methods of fluorescence-based 
genotyping on the ABI3100 sequencer were used. Allelic loss was scored at any informative 
marker if the area under one allelic peak in the tumour was reduced by more than 50% relative to 
the other allele, after correction for the relative peak areas of the alleles found in constitutional 
DNA of the same patient. 
Multiplex ligation-dependent probe amplification (MLPA) analysis and real-time 
quantitative multiplex (RQM-)PCR 
MLPA analysis to determine the copy number of the APC promoter and individual exons was 
performed on polyps with allelic loss at APC using the Salsa MLPA kit P043 APC 
(MRCHolland) according to manufacturer’s instructions. RQM-PCR to determine the copy 
number of APC exon 14 (normalised against human serum albumin (Alb) exon 12) was 
performed as previously described. (16) The assay has previously been shown to be sensitive 
for tumour samples containing less than 30% contaminating normal tissue. (10) 
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4.1.4 Results 
Overall phenotypic assessment 
We have previously shown that disease severity (number of colorectal adenomas) in classical 
FAP patients varies considerably independent of the germline mutation, but that family 
members tend to have similar severities of disease .(17) We searched the published literature 
(details available from authors) for all patients who had germline mutations in the AFAP-
associated regions of APC and with precisely-reported colorectal polyp counts at presentation. 
We then combined these data with our own. Patient age had no significant effect on polyp 
number. We then tested for familial aggregation of disease severity and found good evidence 
for this, both when all families were considered together (p<0.00001, Kruskal-Wallis test) and 
when families with germline mutations in the three AFAP-associated regions of APC were 
analysed separately (p=0.0002, p=0.045, p=0.0005 respectively, Kruskal-Wallis test). Whilst 
some effects of local clinical practice are possible, such strong associations are unlikely to 
result from systematic errors in polyp counting. We then calculated the median polyp count for 
each family irrespective of size, and tested whether this varied among the three groups with  
Somatic mutations in tumours of patients with AFAP-associated germline APC mutations 
Given that our data showed aggregation of disease severity within families, it became more likely 
that the individual kindreds analysed by previous studies (1, 14) had provided only a partial 
description of the genetic pathways of tumorigenesis in AFAP. We first screened colorectal 
tumours from 5’-mutant patients for somatic APC changes (Supplementary Table 4.1.1). We 
found truncating somatic mutations in 9 of 30 (30%) adenomas. Similar to adenomas from 
classical FAP patients with germline mutations before codon 1285 (9-11), all of the truncating 
mutations left either one or two 20AARs in the protein. Just two of the adenomas (7%) harboured 
a detected ‘third hit’, each in the form of loss of the germline mutant allele (Supplementary Table 
4.1.1). Our results were consistent with those reported by Albuquerque et al (10) on the polyps of 
a single 5’ mutant-patient, but differed from those of Spirio et al (1) in that we found no 
mutations at nucleotides 4661-6 or at any other site after the third 20AAR. It was notable that 
while most of the patients of Spirio et al (1) had presented with attenuated polyposis, the patient 
of Albuquerque et al had been reported to have about 100 adenomas and most of our 5’-mutant 
patients had presented with a classical FAP phenotype (Table 4.1.1). The family of Spirio et al 
(1) cannot therefore be considered representative of all patients with mutations in the AFAP-
associated 5’ region of APC. 
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For patients with exon 9 germline mutations, we found truncating somatic mutations in 47/79 
(59%) adenomas (Table 4.1.2, Supplementary Table 4.1.2). Of the total of 50 truncating 
mutations, 33 (66%) were nt4661insA at codon 1554, and this change was always present on the 
germline mutant allele where assignment was possible. (An uncharacterised defect in DNA 
mismatch repair as a cause for this observation was excluded by analysing the microsatellite 
marker BAT26.) Three other mutations leaving three 20AARs (at codons 1518, 1530 and 1537) 
were found. LOH was found in 13/79 (16%) adenomas; this affected the wildtype allele in 9 cases 
and the mutant allele in 4 cases. Thirty-one (39%) adenomas had evidence of ‘thirds hits’, either 
two detected somatic changes or a single identified somatic change on the germline mutant allele. 
The data allowed three main genetic pathways to be identified in the exon 9-mutant patients’ 
polyps with evidence of ‘third hits’ (Table 4.1.2): 
(i) mutation leaving three 20AARs on germline mutant allele, plus loss of the wildtype allele; 
(ii) mutation leaving three 20AARs on germline mutant allele, with undetectable mutation of 
the wildtype allele (most likely towards the 5’ end of the gene, which could not be screened 
in all polyps, and leaving zero 20AARs); 
(iii) mutation leaving one 20AAR on the wildtype allele plus loss of the germline mutant 
allele. 
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Table 4.1.2. Numbers of tumours with evidence of ‘third hits’ (somatic mutation of 
germline mutant allele) at APC in exon 9- and 3’mutant patients’ polyps 
20AAR1 = truncating mutation before first 20AAR, etcetera. Note that these are minimum 
estimates of the true frequency, not only because we could not screen the entire gene for 
mutations in small archival polyps, but also because it was not possible to assign all 
mutations to the germline mutant or wildtype allele. 
 
 
 
For patients with 3’ germline mutations, we found truncating somatic mutations in 35/126 (28%) 
adenomas (Table 4.1.2, Supplementary Table 4.1.3). Of the total of 36 truncating mutations, only 
2 (6%) were nt4661insA. Three other mutations leaving three 20AARs (at codons 1537, 1576 and 
1570) were found. LOH was found in 30/126 (23%) adenomas, equally affecting the wildtype and 
mutant alleles. Twenty (16%) adenomas had either two detected somatic changes or an identified 
somatic change of the germline mutant allele. There was no clear tendency for different families 
to acquire different somatic mutations (Supplementary Table 4.1.3). The data only allowed one 
consistent genetic pathway to be identified in the 3’-mutant patients’ polyps with evidence of 
‘third hits’, namely a mutation leaving one (or two) 20AARs on the germline wildtype allele, plus 
loss of the mutant allele (Table 4.1.2). 
 
Comparison between somatic mutations in the three groups of patients 
The somatic mutation spectra of the 5’- and 3’-mutant patients’ tumours did not differ 
significantly from each other as regards: (i) proportion of mutations leaving one, two or three 
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20AARs (p=0.074, χ22 test); (ii) overall LOH frequency (2/9 versus 30/126, p=0.64); and (iii) 
proportion of tumours with detected ‘third hits’ or an identified somatic change on the germline 
mutant allele (2/9 versus 20/126, p=0.45). However, whilst exon 9-mutant patients had a similar 
frequency of LOH (13/79, 22%, p=0.14) to the other patients, germline exon 9 mutants had a 
higher frequency of mutations that left three 20AARs (36/50 versus 5/45, p<0.001, χ22 test) and a 
higher frequency of tumours with detected ‘third hits’ (31/79 versus 22/156, p<0.001, χ222 test). 
In large part, these associations reflected the fact that nt4661insA was particularly common in the 
exon 9-mutant patients’ tumours and exclusively targeted the mutant germline allele. Overall, our 
data were consistent with a large proportion of polyps in the 5’- and 3’-mutant patients 
developing along the ‘classical’ FAP pathway, their polyps showing similar somatic mutations to 
individuals with germline mutations which leave zero 20AARs (9). Exon 9-mutant patients were, 
however, significantly different from the other two groups of patients. Although not all nt4 
661insA mutations could be assigned to a germline allele, if we made the reasonable assumption 
that all of these mutations were on the germline mutant allele, over half of all tumours from exon 
9-mutant patients had ‘third hits’ (Supplementary Table 4.1.2). These differences could not 
readily be explained by features such as the size or dysplasia of the tumours analysed, which did 
not differ significantly among the three patient groups (details not shown). 
Mechanism of LOH 
We tested the possibility that different LOH events (for example, those involving the germline 
wild type and mutant alleles) were caused by different mechanisms, such as mitotic 
recombination and deletion, which resulted in different gene dosages and functional 
consequences. However, none of 17 tumours with allelic loss (10 with mutant LOH and 7 with 
wild-type LOH) showed copy number changes in the APC promoter region or exons using 
MLPA analysis. We selected for RQM-PCR analysis 10 further tumours (2 with mutant LOH 
and 8 with wild-type LOH) with mean LOH ratios below 0.3 (indicating that contamination 
with normal tissue was low enough not to confound the detection of deletion, (10) but, all 
adenomas showed copy number values between 0.79 and 0.97, consistent with diploid APC 
copy number and LOH by mitotic recombination. 
Early pathways of tumorigenesis in AFAP polyps with ‘three hits’ 
Our data, combined with previous findings (1, 14), showed that a substantial proportion of AFAP 
adenomas have acquired two somatic APC changes, one targeting the germline wildtype and one 
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the germline mutant allele. Consideration of the order in which these somatic changes occur and 
their respective effects on tumour growth and has important implications for determining the 
molecular genetic mechanism underlying AFAP. In AFAP adenomas, initiation of tumour growth 
might require all ‘three hits’ to be present in the tumour cell of origin (‘kick-start’ model). In this 
case, the two somatic mutations could occur in either order without functional consequence. The 
‘kick-start’ model implies that a mechanism exists which results in an increase of the intrinsic or 
effective mutation rate in order to explain the relatively high frequency of such tumours as 
compared to the general population. Alternatively, the ‘second hit’ - necessarily involving the 
germline wild-type allele - might be sufficient for early adenoma growth, with the ‘third hit’ 
(involving the germline mutant allele) being required for subsequent tumorigenesis prior to 
clinical presentation. This ‘stepwise’ model postulates that mutation of the germline wild-type 
allele induces limited clonal expansion (thereby increasing the effective mutation rate), and is 
followed by mutation of the germline mutant allele to give an optimal APC genotype.  
APC mutation data from individual adenomas can be used to distinguish between these 
possibilities, because the ‘kick-start’ and ‘stepwise’ models are expected to leave distinct 
footprints as regards the proportion(s) of somatic mutant allele(s), since these proportions depend 
on the order in which the somatic changes have occurred and some residual adenoma with ‘two 
hits’ is expected in the ‘stepwise’ case (Figure 4.1. 2). 
Consider, for example, polyps with loss of the germline wild-type allele and a somatic 
insertion/deletion mutation on the germline mutant allele. We can measure two ratios of relative 
allelic dosage, one for the germline mutation and the other for the truncating somatic mutation, 
and use these to estimate the proportion of each allelotype in the tumour. Furthermore, we can 
calculate the expected values of these ratios by predicting the proportion of somatic mutant allele 
expected in the tumour under different models of tumorigenesis (Figure 4.1. 2). By comparing the 
observed proportion of the somatic mutant allele with that expected, we can determined whether 
the ‘stepwise’ or ‘kickstart’ model fits better (see Figure 4.1. 2 for details). Similarly, observed 
and expected allele proportions can be determined for adenomas with one somatic 
insertion/deletion mutation on the germline wildtype allele and loss of the germline mutant allele 
(Figure 4.1. 2). For tumours with two truncating somatic mutations, the expected ratio of the two 
mutant alleles under each model can be compared to the ratio measured directly by cloning a PCR 
product  
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Table 4.1.3: Observed and expected frequencies of somatic mutant APC alleles in AFAP 
polyps with ‘three hits’ for ‘kick-start’ and  ‘stepwise’ models of tumorigenesis. αgl = 
proportion of germline wild-type allele in polyp; βgl = proportion of germline mutant allele in 
polyp; βsom = proportion of somatic mutant allele in polyp. Observed αgl βgl frequencies were 
determined from LOH ratios. Observed βsom frequencies were similarly determined from LOH 
ratios generated by PCR amplification of a region encompassing the somatic insertion/deletion 
and subsequent Genescan analysis (using constitutional DNA from patients with germline 
mutations identical to the somatic change for normalisation). The observed ‘third’ to ‘second 
hit’ ratio for polyp  was determined by sequencing 58 clones of a PCR product encompassing 
both somatic changes. 
 
encompassing both changes, sequencing multiple clones and counting how many times each 
allele is represented (Figure 4.1. 2). 
For seven tumours with loss of the germline wild-type allele and a somatic insertion/deletion 
mutation, the observed and expected proportions of the somatic mutant allele were very similar 
to those expected under the ‘kick-start’ model, assuming that the ‘second hit’ was the 
insertion/deletion (on the somatic mutant allele) and the ‘third hit’ was the allelic loss (Table 
4.1.3). Similar results in favour of a ‘kick-start’ model were obtained for three adenomas with 
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one somatic insertion/deletion and loss of the germline mutant allele, and for one adenoma with 
two truncating somatic mutations (Table 4.1.3). 
4.1.5 Discussion  
Our analysis of a relatively large set of AFAP families has shown complexity in the phenotype 
and early genetic pathways of tumorigenesis. The two previous analyses of somatic APC 
mutations in AFAP each focussed on single families, one with a germline mutation in the 5’ 
region of the gene (1) and the other with a mutation in exon 9 (14). These two studies 
unequivocally provided the important and original finding that ‘three hits’ - that is, two somatic 
mutations, including loss or mutation of the germline mutant allele - can occur in AFAP tumours. 
The restricted size of the two studies meant, however, that they were unable to provide further 
conclusions. 
We have found that patients with germline APC mutations in the 5’ and 3’ regions of the gene or 
the alternatively spliced region of exon 9 have a highly variable large-bowel phenotype, in that 
the number of colorectal adenomas varies from almost none to the hundreds or thousands of 
lesions found in classical FAP (3). Although assessment methods necessarily differ among 
clinical centres, our analysis shows that patients with 5’ APC mutations (codons 1-177) are likely 
to have a more severe phenotype phenotype than those with mutations in exon 9 or the 3’ end of 
the gene (>codon 1580). Phenotypic severity also tends to be similar within families, suggesting 
that restricting analyses to single kindreds may not provide accurate assessment of AFAP 
patients. 
Our study has confirmed that ‘three hits’ at APC often occur in AFAP adenomas. In such polyps, 
the ‘third hit’ appears to be required for the initiation of tumorigenesis. Although ‘third hits’ 
might occur at loci other than APC, we have previously found no mutations at beta-catenin in 
AFAP polyps (unpubl. data). In polyps with ‘three hits’ from exon 9-mutant and 3’-mutant 
patients, we have been able to identify specific combinations of APC mutations which tend to 
occur. Exon 9 is alternatively spliced in all normal and neoplastic tissues which we have 
examined (not shown). The combinations of APC mutations almost certainly produce a near-
optimal level of Wnt signalling, comparable with those found in classical FAP (9). Some of the 
combinations – such as R332X-nt4661insA/LOH – strongly suggest that the tumour has 
developed as a result of the functional effects of the germline mutant allele, but other 
combinations of mutations – such as truncating mutation leaving one 20AAR on the wildtype 
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with LOH of the germline mutant – might simply be indicative of a  ‘sporadic’ tumour occurring 
on the background of AFAP. 
In our families, ‘third hits’ were much rarer in 5’- and 3’-mutant patients than in the exon 9 
mutants. These former families’ somatic mutations usually - but not always - resembled those of 
classical FAP patients who have germline mutations before the first 20AAR of the APC protein. 
In many ways, this is the result which would be predicted were the 5’ or 3’ mutations simply to 
cause absent or non-functional protein. 5’ APC mutations probably produce a small amount of 
partially functional APC through use of an internal ribosome entry site (IRES) at codon 184 (18). 
3’-mutant proteins have been reported as being unstable (19), although the reasons for this are 
unknown. It is entirely plausible that the levels of functional APC protein vary among individuals 
with both 5’ and 3’ mutations, for example as a result of modifier alleles. Thus, for an adenoma to 
form, some patients would tend to require ‘third hits’ and others would not. The family of Spirio 
et al (1), for example,  may have been relatively efficient at use of the IRES. Formal testing of 
this hypothesis in vivo would require an exceptionally large, unselected series of tumours and 
patients. 
Our analysis of exon 9-mutant cases further provides further evidence to show that not all AFAP 
patients are the same. ‘Third hits’ were common in these patients’ tumours.  There was a 
markedly increased frequency of mutations which left three 20AARs on the germline mutant 
allele, particularly – but not exclusively - at nt4661, which appears to be a relatively 
hypermutable site. Our view differs somewhat from that of Su et al (14), who proposed that 
insAnt4661 mutations were over-represented in AFAP polyps because both ‘strong’ and ‘weak’ 
mutations were sufficient to severely reduce function of the exon 9- mutant allele. We suggest 
that mutations leaving three 20AARs on the germline mutant allele are common because the 
resulting allelotype R332X-4661insA gives a near-optimal genotype, taking into account loss of 
the germline wildtype allele and alternative splicing of exon 9. Variation in splicing efficiency – 
again through modifier allele action - could explain phenotypic variability in exon 9-mutant 
AFAP, but it appears that many of these patients produce sufficient functional protein by splicing 
out exon 9 that ‘third hits’ are necessary in most polyps. 
The reason why AFAP patients develop fewer polyps than classical FAP patients is evident, in 
that ‘three hits’ are often needed to produce the near-optimal genotype. We do not, however, 
claim that all polyps from patients with AFAP-associated APC mutations require ‘three hits’. 
Even allowing for the imperfections of mutation screening and LOH analysis in archival 
specimens, we were able to analyse the fresh-frozen adenomas comprehensively and found many 
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without ‘three hits’. Moreover, several polyps from our patients had somatic mutations which 
would have been predicted from a ‘two hit’ model of optimal Wnt signalling. Currently, we 
cannot explain why in a single patient, some polyps seem to require ‘three hits’ and others do not, 
but it is possible that ‘third hits’ at other loci can substitute for APC mutation. Another possibility 
is that selective constraints on the diminished APC function needed for tumorigenesis are ‘just 
right’ (1, 10) at some times, but weaker at others, for example during development or when tissue 
is undergoing repair. 
The genetic analysis of colorectal tumours from patients with germline mutations inAFAP-
associated regions of APC, by this study and others, has revealed a novel mechanism underlying 
the genotype-phenotype association in this tumour syndrome, namely an requirement for ‘three 
hits’ in at least some AFAP adenomas. This finding mustbe viewed in the framework of the 
model of optimal combinations of APC mutations, ratherthan simple loss of protein function. 
More than one different combination of APC mutationscan provide near-optimal Wnt signalling 
in AFAP. However, not all AFAP patients are thesame. Given that assembling a very large series 
of AFAP patients is extremely difficult, it isnot easy to decide on what is the ‘typical’ AFAP 
phenotype or somatic genotype. In the seven families with 5’ APC mutations studied to date ((1, 
10) and this study), about 15-20% of polyps seem to acquire ‘three hits’, but only Spirio et al (1) 
found a high frequency of nt4661insA. In the six 3’-mutant families studied (all from this study), 
the frequency of ‘third hits’ seems similar to that of the 5’-mutants. Six exon 9-mutant families 
have been studied (14) and this study) and almost all of these show evidence of a high frequency 
of ‘third hits’– we estimate a minimum of 50% in our study. In addition, there appear to be 
genetic factors apart from the germline APC mutation that influence disease severity, as 
evidenced by the tendency for polyp numbers to be similar within families. The phenotypic and 
somatic molecular heterogeneity in AFAP means that clinical management of patients with AFAP 
associated mutations must be empirical. Accurate prediction of phenotype may only be possible 
when factors, such as modifier genes, that influence genetic pathways and diseas eseverity are 
identified. 
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Supplementary tables and figures 
 
 
Supplementary Table 4.1.1. Somatic APC mutations and allelic loss in tumours from 
AFAP patients with 5’ germline mutations. All tumours with mutation or LOH are shown. 
FS = frameshift; LOH = loss of heterozygosity; wt = germline wild-type allele; mut = germline 
mutant allele, where this assignment was possible 
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Supplementary Table 4.1.2. Somatic APC mutations and allelic loss in 79 tumours from 
AFAP patients with germline mutations in the alternatively spliced region of exon 9. 
See Supplementary Table 4.1.1 for abbreviations. 
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Supplementary Table 4.1.3. Somatic APC mutations and allelic loss in 126 adenomas 
from AFAP patients with 3’ germline mutations. See Supplementary Table 4.1.1 for 
abbreviations. 
§ 
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Figure 4.1. 2. Pathways of tumorigenesis in AFAP polyps with ‘three hits’. 
The Figure 4.1.2. illustrates the possible sequences in which somatic mutations/allelic loss may occur in 
AFAP polyps with ‘three hits’, as well as the possible functional effects of these changes. The expected 
proportions βgl, βsom and βgl are shown. = germline mutation; X, * = truncating somatic mutation; LOH 
= loss of heterozygosity by mitotic recombination; βsom = proportion of somatic mutant allele in polyp; 
αgl = proportion of germline wild-type allele in polyp; βgl = proportion of germline mutant allele in polyp 
 (A) Loss of the germline wild-type allele and truncating somatic mutation In a ‘kick-start’ model these 
changes can occur in either order (i) or (ii) and tumour growth ensues once both somatic changes have 
occurred; in a ‘step-wise’ model loss of the germline wild-type allele leads to limited clonal expansion 
and is followed by the truncating somatic mutation which promotes further tumour growth. (B) Loss of 
the germline mutant allele and truncating somatic mutation In both the ‘kick-start’ (i) and the ‘step-wise’ 
(ii) model the truncating somatic mutation precedes loss of the germline mutant allele, but in the ‘kick-
start’ model, both changes are required for tumour growth. (C) Two truncating somatic mutations In a 
‘kick-start’ model (i), these changes can occur in either order and tumour growth ensues once both 
somatic changes have occurred; in a ‘step-wise’ model (ii), somatic mutation of the germline wild-type 
allele causes limited clonal expansion and is followed by somatic mutation of the germline mutant allele 
which promotes further tumour growth. For each model of scenarios (A) and (B), the expected proportion 
of the somatic mutant allele (βsom) in the polyp can be determined from the proportions of the germline 
wild-type (αgl) or mutant (βgl) allele as shown. αgl and βgl can be estimated from the LOH ratio. For 
scenario (C) the expected ratio of the two somatic alleles is 1:1 for the ‘kick-start model’, but lies 
between 1:4 and 1:1 for the ‘step-wise’ model with the minimum estimate (*) assuming a mutation 
detection sensitivity of 20%. 
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CHAPTER 4.2 
4.2 Prevalence of MYH germline mutations in Swiss APC mutation-negative 
polyposis patients  
(Russell A, Zhang J, Luz J, Hutter P, Chappuis P, Berthod C, Maillet P, Mueller H, 
Heinimann K. (published in Int. J. Cancer: 118, 1937–1940 2006) (Equally contributed)  
 
4.2.1 Abstract 
In 10-30% of patients with classical familial adenomatous polyposis (FAP) and up to 90% of 
those with attenuated (<100 colorectal adenomas; AFAP) polyposis, no pathogenic germline 
mutation in the adenomatous polyposis coli (APC) gene can be identified (APC mutation-
negative). Recently, biallelic mutations in the base excision repair gene MYH have been shown to 
predispose to a multiple adenoma and carcinoma phenotype. This study aimed to (i) assess the 
MYH mutation carrier frequency among Swiss APC mutation-negative patients and (ii) identify 
phenotypic differences between MYH mutation carriers and APC/MYH mutation-negative 
polyposis patients. Seventy-nine unrelated APC mutation-negative Swiss patients with either 
classical (n = 18) or attenuated (n = 61) polyposis were screened for germline mutations in MYH 
by dHPLC and direct genomic DNA sequencing. Overall, 7 (8.9%) biallelic and 9 (11.4%) 
monoallelic MYH germline mutation carriers were identified. Among patients with a family 
history compatible with autosomal recessive inheritance (n = 45), 1 (10.0%) out of 10 classical 
polyposis and 6 (17.1%) out of 35 attenuated polyposis patients carried biallelic MYH alterations, 
2 of which represent novel gene variants (p.R171Q and p.R231H). Colorectal cancer was 
significantly (p < 0.007) more frequent in biallelic mutation carriers (71.4%) compared with that 
of monoallelic and MYH mutation-negative polyposis patients (0 and 13.8%, respectively). On 
the basis of our findings and earlier reports, MYH mutation screening should be considered if all 
of the following criteria are fulfilled: (i) presence of classical or attenuated polyposis coli, (ii) 
absence of a pathogenic APC mutation, and (iii) a family history compatible with an autosomal 
recessive mode of inheritance. 
4.2.2 Introduction 
Familial adenomatous polyposis (FAP; OMIM entry no.175100) is an autosomal dominantly 
inherited colorectal cancer (CRC) predisposition caused by germline mutations in the 
adenomatous polyposis coli (APC) gene and characterized by the development of hundreds to 
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thousands of adenomatous polyps throughout the intestinal tract.[1] Attenuated FAP (AFAP) 
represents a clinical variant of classical FAP, associated with multiple (<100) colorectal 
adenomas and caused by mutations in the most 5  or 3  regions of APC or in the alternatively 
spliced region of exon 9(1,2,3). With routine screening techniques failing to detect pathogenic 
APC germline mutations in 10-30% of classical FAP patients and in up to 90% of AFAP 
patients,(4) investigations about the role of other polyposis predisposition genes are topical. 
Recently, Al Tassan et al. demonstrated that biallelic germline mutations in the human 
homologue of the base excision repair gene MutY (MYH) cause a phenotype of multiple colorectal 
adenomas and carcinomas, thus, describing for the first time an autosomal recessively inherited 
CRC predisposition(5,6). The DNA glycosylase MYH removes adenines from mispairs with 8-
oxoguanine that occur during replication of oxidized DNA. Failure to correct these mispairs 
consequently leads to G:C T:A transversion mutations, a typical footprint  of oxidative DNA 
damage.(7)The observation of an excess of transversion mutations in tumors eventually led to the 
discovery of MYH-associated polyposis (MAP). A number of studies have already been 
conducted in attempts to establish the extent to which germline mutations in the MYH gene may 
contribute to individuals with an AFAP phenotype(6)(8)(9). As a result, biallelic MYH germline 
mutations have been attributed to 1-3% of all unselected CRC patients. This nation-wide study 
aimed to (i) assess the frequency of MYH mutation carriers in 79 unrelated Swiss patients 
presenting with either classical or attenuated polyposis and in whom no pathogenic APC germline 
mutation could be identified and (ii) to identify phenotypic differences between biallelic mutation 
carriers, monoallelic mutation carriers and APC/MYH mutation-negative patients. 
4.2.3 Patients and Methods 
Patients 
This nation-wide study investigated 79 ostensibly unrelated Swiss index patients referred 
between 1994 and 2004 to either the Research Group Human Genetics, Division of Medical 
Genetics, Basel, or the Unit of Genetics, Institut Central des Hôpitaux Valaisans, Sion, 
Switzerland, because of classical ( 100 polyps, n = 18) or multiple adenomas/attenuated (5-99 
polyps) FAP (AFAP; n = 61). In all patients, no germline APC mutation could be identified by 
means of the protein truncation test, single strand conformation polymorphism or direct DNA 
sequencing (patients thereafter referred to as APC mutation-negative).[10] Forty-five patients 
displayed a family history compatible with autosomal recessive inheritance; in the remainder 
there was either evidence for vertical transmission or no detailed family history available. In 
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addition, 100 control Swiss individuals were enrolled so as to establish the carrier frequency of 
previously reported MYH variants as well as novel mutations of unknown pathogenic 
significance in unaffected individuals. Informed consent for the study was obtained from all 
individuals investigated. Patients were considered as anonymous cases, and the results of the 
various genetic analyses were independently checked by at least 2 assessors. 
DNA extraction 
Genomic DNA was isolated from EDTA blood, using methods previously described by Miller et 
al (11). Briefly, 10 ml blood was mixed with 30 ml of EL buffer (155 mM NH4Cl, 10 mM 
KHCO3, 1 mM EDTA, pH 7.4) and left on ice for 15 min. The lysate was centrifuged at 2000g 
for 10 min, washed twice with EL buffer and the intact leukocyte pellet resuspended in NL buffer 
(10 mM Tris.HCl, pH 8.2, 400 mM NaCl, 2 mM Na2EDTA, 1% SDS and 200 g/ml proteinase 
K) and incubated overnight at 37ºC. The next day, 1 ml of 6 M NaCl was added and vigorously 
shaken, followed by centrifugation to remove cellular proteins. The supernatant containing the 
DNA was placed in a fresh tube and the DNA precipitated with ethanol. The resulting DNA pellet 
was washed with 70% ethanol, dried briefly and then suspended in 1 ml of TE buffer (10 mM 
Tris.HCl, pH 7.5, 0.1 M EDTA). 
MYH mutation analysis 
In 57 (72%) patients (15 FAP and 42 AFAP), the entire MYH coding sequence was analyzed by 
direct DNA sequencing. An additional 22 patients (3 FAP and 19 AFAP) were exclusively 
screened for mutations in exons 7 and 13 in which the most common pathogenic mutations in the 
Caucasian population, p.Y165C and p.G382D, occur. Each time a heterozygous MYH mutation 
was identified, the entire gene was subsequently analyzed by direct DNA sequencing (exons 2, 5, 
8 and 12) and dHPLC (exons 1, 3, 4, 6, 9, 10, 11, 14, 15, 16) to identify/exclude the presence of a 
second germline mutation.Exon specific primer pairs were used to amplify the 16 exons of MYH 
(HUGO ID: MUTYH; Genbank accession no. NM_012222), including the respective exon-intron 
boundaries (primer sequences and PCR conditions available from the authors upon request). 
Twenty-five microliters of PCR reaction mixture contained 50 ng of genomic DNA, 10 pmol of 
each primer and a PCR mastermix at 1.5 mM MgCl2, according to the manufacturer's instructions 
(Invitrogen, Basel, Switzerland). All PCR reactions were done on a Hybaid OmnE thermocycler 
(Catalys AG, Wallisellen, Switzerland). 
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dHPLC 
As a prescreening method to detect DNA sequence changes, dHPLC was performed using the 
3500HT WAVE nucleic acid fragment analysis system (Transgenomic, Crewe, UK). Melting 
temperatures for dHPLC were predicted by the Wavemaker software version 4.1.42 
(Transgenomic) (dHPLC melting temperatures available from the authors upon request). Where 
different elution profiles were observed in comparison with the control samples run in parallel, 
direct DNA sequencing was performed to characterize the nature of the sequence alteration. 
Direct DNA sequencing  
For DNA sequencing, PCR products were purified using the QIAquick PCR Purification kit 
(Qiagen, Basel, Switzerland). The sequencing reaction was performed using the Big Dye 
Teminator Cycle Sequencing kit (Applied Biosystems, Rotkreuz, Switzerland), according to the 
manufacturers' guidelines. Following purification using the DyeEx 2.0 Spin Kit (Qiagen, Basel, 
Switzerland), sequencing products were analyzed on an ABI PRISM 310 Genetic Analyser 
(Applied Biosystems). Germline mutations identified in MYH were confirmed by sequencing in 
both, forward and reverse, directions, and from at least 2 independent PCR products. Germline 
mutations p.Y165C and p.G382D were independently confirmed by restriction enzyme digests, 
using IlaI and BglII, respectively. 
Statistical analysis 
Statistical comparison of patients' features, encompassing phenotypic characteristics (gender, age 
at diagnosis, polyp number, extracolonic manifestations, family history) and mutational status 
was performed using the 2 and Fisher's exact test for categorical variables, or Student's t-test for 
continuous variables, with all of the probabilities reported as two-tailed ps, considering a p value 
of <0.05 to be statistically significant. 
4.2.4 Results 
Seventy-nine APC mutation-negative Swiss polyposis patients from the Basel (n = 58) and Sion 
(n = 21) medical genetic centers were investigated for the presence of MYH germline alterations. 
Twenty-three percent of the individuals were referred because of suspected classical FAP (n = 
18), whilst the majority exhibited an attenuated or multiple adenoma phenotype (n = 61). 
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Table 4.2.1. Phenotypic Features and Germline Mutations Identified in MYH Mutation 
Carriers1 
 
MYH  
Patient 
ID Sex Age 
Polyp 
No. CRC 
Extracolonic 
disease 
1st 
Mutation 2nd Mutation 
Biallelic MYH mutation carriers 
1775/01 M 38 <100 Yes Yes p.G84fs p.W138_M139ins 
IW 
1828/01 F 42 <100 Yes No p.Y165C p.Y165C 
1859/01 M 33 <100 No No p.Y165C p.Y165C 
2013/01 M 50 <100 Yes No p.G382D p.G382D 
2073/01 F 60      50 No No p.Y165C p.R171Q 
2184/01 M 48 >100 Yes No p.G382D p.G382D 
2185/01 M 48     74 Yes No p.Y165C p.R231H 
Monoallelic MYH mutation carriers 
1384/01 F 20 Multiple No Yes p.G382D None detected 
1665/01 F 54 >100 No No p.I209V None detected 
2145/01 M 40     70 No No p.Y165C None detected 
2243/01 M 49     50 No No p.Y165C None detected 
2261/01 F 69 >100 No No p.Y165C None detected 
DFAP 
17 
F 34     20 No Yes p.G382D None detected 
DFAP 
82 
M 58 >100 No No p.G382D None detected 
DFAP 
99 
F 63    43 No No p.G382D None detected 
SA 453 M 41 5 No No p.G382D None detected 
 1 Patient 1775/01 has previously been reported by Sieber et al.(8) 
MYH mutation analysis 
The complete coding sequence of the MYH gene was investigated in 57 index patients. In addition, 
22 patients were screened for alterations in exons 7 and 13, which harbor the most common 
pathogenic mutations, p.Y165C and p.G382D. Overall, 7 (8.9%) biallelic and 9 (11.4%) 
monoallelic MYH germline mutation carriers were identified. According to the clinical 
classification, 1 (5.6%) out of 18 FAP and 6 (9.8%) out of 61 AFAP patients harbored a biallelic 
MYH mutation. If only individuals with a family history compatible with autosomal recessive 
inheritance were considered (n = 45), 10.0% (1/10) of patients with classical polyposis and 17.1% 
(6/35) of AFAP patients harbored biallelic MYH germline mutations (Table 4.2.I).  
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In addition to the mutations p.Y165C and p.G382D, which accounted for 43% and 29% of mutant 
alleles in the biallelic patients, respectively, 2 novel alterations were detected in AFAP patients 
compound heterozygote for p.Y165C/p.R171Q and p.Y165C/p.R231H (Figs. 1a and 1b). One 
FAP patient, who was found to be a compound heterozygote with a p.G84fs/p.W138_M139insIW 
mutation, has been previously reported by Sieber et.a l (8). The healthy parents of this individual 
were available for investigation and were found to be heterozygous carriers of the p. 
W138_M139insIW and the p.G84fs alteration, respectively. Although the pathogenicity of 
p.R171Q and p.R231H remains to be established by functional studies, such gene alterations were 
not observed in 200 chromosomes from Swiss control samples. Furthermore, the amino acid 
positions are evolutionary highly conserved across distantly related species (E. coli, S. pombe, 
mouse, rat and human).  
 
Figure 4.2.1. Sequencing chromatograms displaying the 2 novel MYH germline variants marked by an 
asterisk (*). (a) c.512G>A, p.RI7IQ (heterozygote); (b) c.693G>A, p.R231H (heterozygote). 
 
Nine patients were identified as monoallelic MYH mutation carriers, with the p.G382D mutation 
present in 5 (56%) of them (Table 4.2.1). In the remaining 63 (80%) patients, no pathogenic 
MYH mutations could be identified. The previously described polymorphisms in exon 2 (c.64G 
> A; p.V22M) and exon 12 (c.972G > C; p.Q324H) were detected with allele frequencies of 6% 
and 17%, respectively, similar to that of a Swiss control sample population (200 chromosomes) 
assessed in parallel (2% p.V22M and 12% p.Q324H).  
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Genotype-phenotype comparisons 
The phenotypic features of the 7 biallelic MYH mutation carriers are depicted in Table 4.2.1, with one 
of them displaying classical FAP. In 5 (71%) patients, CRC had been diagnosed at a median age of 48 
years (IQR 10.5, range 33-60 years), with 3 of them located at  proximal to the splenic flexure. The 
family history in all biallelic mutation carriers corresponded to an autosomal recessive mode of 
inheritance. Remarkably, in 3 out of 11 siblings of patient 2073/01 (p.Y165C/p.R171Q) a CRC had 
been diagnosed at a median age of 51 years (range 49-54). Except for patient 1775, in whom 
duodenal adenomas had been detected, no apparent extracolonic disease manifestations were 
observed in the other biallelic mutation carriers. 
Among the 9 monoallelic MYH mutation carriers (Tables 4.2.1 and 4.2.2),  4 patients (no. 1384/01, 
2243, DFAP17 and DFAP 82) had siblings with either CRC or polyps reported. With respect to 
extracolonic disease manifestations, a facial lipoma was observed in patient DFAP17 and a duodenal 
adenocarcinoma at age 20 in patient 1384/01.  
Table 4.2.2. Phenotypic Characteristics of Biallelic MYH Mutation Carriers, Monoallelic 
Mutation Carriersand APC/MYH Mutation-Negative Patients with a Family History Compatible with 
autosomal Recessive Inheritance 
  
Biallelic MYH 
mutation carriers 
(n = 7) 
Monoallelic 
MYH mutation 
carriers (n = 9) 
MYH mutation-
negative patients 
(n = 29) 
Sex 
   Male 5 (71)1 5 (56) 18 (62) 
   Female 2 (29) 4 (44) 11 (38) 
Clinical classification 
 
F AP (   100 polyps) 
1 (14) 3 (33) 6 (21) 
   AFAP (<100 polyps) 6 (86) 6 (67) 23 (79) 
Age at diagnosis (yr) 
   Median 48 49 48 
   IQR 10.5 20.8 20 
   Range 33-60 20-69 22-77 
Colorectal cancer 
   Present 5 (71) 0 4 (14) 
   Absent 2 (29) 9 (100) 25 (86) 
Extracolonic disease 
   Present 1 (14) 2 (22) 4 (14) 
   Absent 6 (86) 7 (78) 25 (86) 
FAP:familial adenomatous polyposis;  AFAP, attenuated FAP. 
  1 Values given in parentheses indicate percentages. 
 97
                 Chapter 4.2  
Twenty-nine (46%) out of 63 MYH mutation-negative patients had a family history of CRC 
and/or multiple polyps/polyposis compatible with an autosomal recessive mode of inheritance 
and could, therefore, be included in the genotype-phenotype analysis (Table 4.2.II). Comparing 
the phenotypic properties of biallelic MYH mutation carriers, monoallelic mutation carriers and 
APC/MYH mutation-negative polyposis patients, colorectal cancer was significantly more 
frequent in biallelic mutation carriers than in the other subgroups (71% vs. 0% and 14%, 
respectively; 2 14.5, p < 0.001). Median age at diagnosis was similar between the 3 subgroups 
(48, 49 and 48 years, respectively). No further statistically significant phenotypic differences 
with respect to polyp number, age at diagnosis or extracolonic disease was observed. 
4.2.5 Discussion   
In this nation-wide survey on 79 Swiss APC mutation-negative polyposis patients, 9% were found 
to harbor biallelic (n = 7) and 11% monoallelic (n = 9) germline mutations in the base excision 
repair gene MYH. Considering only patients with a family history compatible with autosomal 
recessive inheritance, biallelic MYH mutation carriers were observed in 10% (1/10) of patients 
with classical and in 17% (6/35) of those with attenuated polyposis, respectively. No MYH 
alterations were identified in patients exhibiting a family history suggestive of an autosomal 
dominant inheritance pattern. 
In addition to the most common pathogenic missense mutations, p.Y165C and p.G382D(5)(6)(8)(12). 
2 novel alterations in the MYH gene p.R171Q and p.R231H were detected. Two hundred control 
chromosomes, assessed in parallel, did not harbor these missense changes, which proved to be target 
amino acids highly conserved across 5 distantly related species. Furthermore, whilst p.R171 
constitutes part of a 6 helix barrel domain that contains the Helix-Hairpin-Helix motif, p.R231 lies 
within the alpha-8 helix making up the cluster domain. Together they form part of a DNA binding 
complex, where 9 lysines and 5 arginines form an electrostatically positive DNA interaction surface 
(13). Clearly, functional studies are needed to ascertain the pathogenicity of these novel mutations. 
Moreover, since the parents of the individuals harboring these gene alterations were not available for 
screening, we cannot exclude the possibility that the mutations in the compound heterozygotes may 
lie on the same allele. 
In our study population, the overall allele frequency of the missense variants p.Y165C and p.G382D 
amounted to 5.7% (9/158) and 5.1% (8/158), respectively; if only patients with a family history 
compatible with an autosomal recessive mode of inheritance were considered, the allele frequencies 
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raised to 10% (9/90) and 8.9% (8/90). In contrast, these alterations were not present in Swiss control 
samples (0/100), similar to reports on Finnish blood donors (0/424) and healthy British controls 
(2/100) (5)(12). This further substantiates the view that the frequency of the p.Y165C and p.G382D 
mutations in the general population is too low to justify large-scale mutation screening (7). 
The overall frequencies of biallelic mutation carriers did not significantly differ between patients 
displaying a classical (5.6%) and those displaying an attenuated (9.8%) FAP phenotype that is 
similar to reports by Sieber et al. who identified biallelic mutations in 7.5% and 5% of patients, 
respectively (8). The frequency of monoallelic mutation carriers, however, was significantly higher 
in our study group (11.4% compared with that of 3.9% as reported by Sieber et al (8). which may 
reflect ethnic and geographic differences between the populations studied. Six (86%) out of 7 
biallelic MYH mutation carriers were found to have less than 100 polyps at the time of diagnosis and 
5 (71%) had developed colorectal cancer. Thus, in contrast to initial studies reporting classical 
disease (>100 adenomas) in all biallelic mutation carriers (6), the MYH associated-polyposis 
phenotype in our patients is predominantly an attenuated one, which is in accordance with recent 
data from Enholm et al.(12) ,who investigated a population-based series of Finnish CRC patients. 
On the basis of clinicopathological features, it is virtually impossible to discriminate biallelic 
from monoallelic MYH mutation carriers and MYH mutation-negative polyposis patients who 
have a family history compatible with autosomal recessive inheritance. In all groups, median age 
at diagnosis did not differ significantly, and the occurrence of extracolonic disease was similar. 
Colorectal adenocarcinomas, however, were significantly (p < 0.001) more frequent among 
biallelic as compared to that of monoallelic MYH mutation carriers and MYH mutation-negative 
polyposis patients. 
In conclusion, biallelic MYH germline alterations were identified in 15.5% of Swiss APC 
mutation-negative patients with a family history compatible with autosomal recessive inheritance. 
Biallelic mutation carriers were more frequently observed in AFAP patients compared to those 
with classical FAP (17% vs. 10%). Colorectal cancer was significantly more frequent in biallelic 
as compared to monoallelic mutation carriers or those without MYH alterations. Based on our 
experience and earlier reports, we suggest that MYH mutation screening should be offered to 
individuals who fulfill all of the following criteria: (i) presence of classical or attenuated 
polyposis, (ii) absence of an APC germline mutation and (iii) a family history compatible with an 
autosomal recessive mode of inheritance. It remains to be determined within the framework of 
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international collaborative studies if monoallelic MYH mutation carriers, compared to the general 
population, may actually be at an increased risk for developing colorectal cancer (14). 
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CHAPTER 5  
5. General Discussion 
In this thesis, our investigation have focused on determining the prevalence of large genomic 
rearrangements and the germline mutations in novel susceptibility genes within major hereditary 
colorectal cancers syndromes: hereditary nonpolyposis colorectal cancer (HNPCC), familial 
adenomatous polyposis (FAP) and MYH - Assoicated Polyposis (MAP). In addition, we have 
characterized the second somatic mutation in tumors from MMR and APC gene mutation carriers 
to address the mechanisms of tumor initiation in HNPCC and FAP.  
All these investigations are aimed to understand tumor initiation and progression in hereditary 
colorectal cancer in order to enable early diagnosis and devise optimal medical therapy and 
prevention of cancers.  
Prevalence of large genomic rearrangements in HNPCC 
Hereditary Nonpolyposis Colorectal Cancer (HNPCC) is an inherited cancer syndrome caused by 
a deficiency in the DNA mismatch repair system. The majority of mismatch repair (MMR) gene 
mutations have been detected in the MLH1 and MSH2 genes. Most mutations are substitutions, 
small insertions and deletions. However, standard methods of mutation analysis do not detect 
large genomic rearrangements which may account for a significant proportion of MLH1 and 
MSH2 mutations. Two novel methods (QMPA and MLPA) were established and compared by the 
detection of large deletions in 35 mutation negative Swiss HNPCC patients. Twenty - one of them 
presented with tumors exhibiting microsatellite instability and 16 of them showing 
immunohistochemical loss of either the MLH1 or MSH2 gene product.  Four large genomic 
deletions were detected by QMPA and three of them could be confirmed by MLPA. The results 
indicated that genomic deletions account for a substantial fraction of mutations in both the MLH1 
and MSH2 genes. Two methods applied for large deletion screening, QMPA and MLPA are 
readily identifying the deletions in the patients, albeit with variable specificity. Compared to 
MLPA, the QMPA technique is difficult to establish and standardize the PCR conditions to obtain 
reproducible results. Therefore, MLPA to QMPA is better suited for the routine genetic testing 
for large genomic rearrangements.  
Prevalence of MYH germline mutations in FAP patients  
FAP accounts for approximately 0.1-1% of all colorectal cancers. Classical FAP is characterized 
by the presence of hundreds to thousands of adenomatous colorectal polyps. The majority of 
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classical FAP patients carry mutations in the APC gene.  However, in 10-30% of patients with 
classical FAP and up to 90% of those with attenuated FAP, no pathogenic germline alterations in 
APC gene can be identified. Recently, homozygous mutations in the MYH gene have been shown 
to predispose to a multiple adenoma and carcinoma phenotype. In an attempt to assess the 
prevalence of MYH mutation carriers among mutation negative polyposis patients and to identify 
possible phenotypic differences between MYH mutation carriers and APC/MYH mutation 
negative polyposis patients, 79 unrelated APC mutation negative Swiss patients were screened for 
MYH by dHPLC and direct DNA sequencing. 9% of them were found to harbor biallelic (n=7) 
and 11% monoallelic (n=9) germline mutations in the MYH gene. Considering only patients with 
a family history compatible with autosomal recessive inheritance, biallelic MYH mutation carriers 
were observed in 10% of patients with classical and in 17% of those with attenuated polyposis. 
Two MYH mutation hotspots in p.Y165C and p.G382D account for 43% and 29% mutant alleles 
in the biallelic patients. Biallelic MYH germline mutations were identified in 15.5% of Swiss APC 
mutation negative patients with a family history compatible with autosomal recessive inheritance. 
They were more frequently observed in AFAP patients rather than in those with classical FAP. 
Colorectal cancer was significantly more frequent in biallelic than in monoallelic mutation 
carriers or in those without MYH alterations.  From these study, we suggest that MYH mutation 
screening should be offered to individuals if all of the following criteria are fulfilled: (1) presence 
of classical or attenuated polyposis and early on-set CRC (2) absence of an APC germline 
mutation, and (3) a family history compatible with an autosomal recessive mode of inheritance. 
Characterization of the Somatic mutation in tumors from MMR and APC gene mutation carriers  
Generally, in most hereditary cancer predispositions, the first hit is inherited in an autosomal 
dominant type [80]. According to Knudson’s “two hit” hypothesis, in hereditary cancers, only one 
mutated copy in a given tumor suppressor gene (TSG) is not enough to enable cancer initiation, a 
second somatic mutation of wild-type allele of TSG is necessary for cancer development [81]. In 
sporadic cancers, two somatic mutations of TSG need to occur in one somatic cell to initiate 
cancer development.  
Thus the germline mutation carriers get much greater chance than general population to get 
cancer since they already harbor the first germline mutation in all the cells of the body [90] . 
Colorectal cancer is an excellent model to study the genetic mechanisms for tumor initiation and 
progression [74]. Major genes like APC and MMR genes involved in major familial colon cancer 
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syndromes have been well characterized. However, little is known about the second somatic hits 
in HNPCC and AFAP tumorigenesis.  
Characterization of second hit mechanism in Hereditary Nonpolyposis Colorectal Cancer 
(HNPCC) 
Tumor development in HNPCC is believed to be initiated by the loss function of the DNA 
mismatch repair (MMR) system. DNA mismatch repair deficiency results from both the germline 
and somatic mutation in the affected MMR gene such as MLH1 and MSH2 in a cell. It is also 
known that aberrant promoter methylation of a DNA mismatch repair is associated with loss 
function of MMR.  
  
In this thesis, we performed a comprehensive analysis of second hit in tumors of well-defined set 
of Swiss and Finnish HNPCC patients carrying large deletions in MLH1 or MSH2 gene. We 
aimed to define its contribution to somatic inactivation of the remaining wildtype allele. 
Nine cancers from 5 Swiss MLH1 or MSH2 large genomic carriers and 7 tumors from 7 Finnish 
MLH1 or MSH2 deletion carrierrs were investigated. These 16 tumors are: 11 of them are 
adenocarcinomas of the colon, 2 endometrium cancers, 1 stomach cancer, 1 urothelial carcinoma 
and 1 astrocytoma (brain tumor). Most of them were exhibiting high MSI. Only two carcinomas 
(urothelial carcinoma of patient 2227 and colon adenomcarcinoma of patient 1676) showed low 
microsatellite instability (MSI). Pathological reports were available of all Swiss tumors. Within 5 
Swiss large genomic deletion carriers, 5 tumors showed identical somatic mutation to their 
germline mutation (Chapter 3.2, Table 3.2.2a). 2 Tumors out of 7 Finnish tumors also showed 
homozygous somatic deletion. One colorectal and one urothelial carcinoma showed loss of one 
exon only. No large genomic deletions and duplications were detected in the remaining tumors (2 
CRCs, 1 ovarian and 1 endometrial cancer). Thus, our findings from two independent sets of 
patients indicate that homozygous mutation of somatic cell is a frequent event in HNPCC (6 out 
of 11 CRCs; 55%). Remarkably, none of the Swiss or Finnish tumor specimens showed evidence 
for large somatic deletions encompassing the entire respective gene locus (LOH). 
In addition to these results, we were able to collect data from one sporadic cancer patient who 
carrys a de novo germline mutation (c.666dupA) in the MLH1 gene.  The patient is 31 years old. 
The tumor developed in the left side of the colon like other sporadic colon cancer. The somatic 
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mutation that was found in the colorectal carcinoma of this patient was identical to its germline 
mutation (C.666dup A). MLPA results showed no LOH in his tumor.  (Chapter 3.3) 
There are several possible mechanisms leading to this homo/hemizygosity mutation in HNPCC 
tumors. Among them are: loss of the complete wild type allele, complete deletion of the gene 
locus of the wild type allele, loss of the chromosome harboring the wild-type allele followed by 
chromosomal reduplication, mitotic recombination, restricted recombination like gene conversion 
[120]. Multiplex ligation-dependent probe amplication (MLPA) and microsatellite marker 
analysis flanking the gene loci on the respective chromosome were applied to distinguish between 
them. The results of those experiments ruled out the following possibilies: loss of the complete 
wild type allele, complete deletion of the gene locus of the wild type allele, loss of the 
chromosome harboring the wild-type allele followed by chromosomal reduplication and mitotic 
recombination except restricted recombination. The data pointed to locus-restricted 
recombination as the putatitive mechanism. 
Locus-restricted recombination, i.e gene conversion is a possible consequence of selection for 
reduced rates of unequal exchange between repeated DNA sequences for which the copy number 
is subject to stabilizing selection. The repeated DNA sequences, expecially short interspersed 
nuclear elements (SINE) like Alu elements may also contribute to hereditary disease including 
cancer [117]. Alu sequences are 300 base pair long and are classified as short interspersed 
elements (SINEs) amongst the class of repetitive DNA elements.  It is estimated that about 10% 
of the mass of human genome consists of Alu sequences [119] . Alu insertion has been implicated 
in several inherited human diseases including cancers. Alu repeat elements have been already 
shown to be involved in germline MLH1/MSH2 rearrangements by several studies [118]. Based 
on this hypothesis, we analyzed the genome sequences of MLH1/MSH2 by repeatmarker program 
in order to assess the frequency and type of DNA repeats inside (UCSC genome analysis website: 
http://genome.ucsc.edu/) (Figure 1).  
Figure 1 depicts the number of repeat sequences in all introns involved in locus-restricted 
recombination in our patients. Interestingly, all intronic regions involved in the sequence were 
regions rich in repeated sequences.  
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Figure 5.1: Distribution of Alu sequences within the introns of MLH1 and MSH2 gene. Intron 
sequences were analysis by RepeatMarker programe (MSH2 gene ensembl ID ENSG00000095002, MLH1 
gene Ensembl ID ENSG00000076242). LINE: Long interspersed nuclear element . Alu sequence: a  family 
of short repeat sequence (<300bp) through the human genome 
Unequal recombination often occurs intrachromosomally, resulting in large genomic 
rearrangements and more complex chromosomal abnormalities. It has been reported that the 
unequal crossing over mediated by Alu repeats is a possible principle factor in tumor progression 
through loss of heterozygosity (LOH) and genomic rearrangement [120]. The mechanism implies 
that high density Alu repeats decreased the sensitivity of base pairing fidelity that would 
presumably allow recombination to happen between more poorly matched homologous [117]. 
Our results support the assumption that the somatic mutation identical to the one in the germline 
in tumors of HNPCC patients is due to locus-restricted recombination (i.e, gene conversion), most 
likely caused by high density Alu sequences within the introns of the deleted regions.  
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In additon to Alu repeats, Figure 1 also shows LINE (long interspersed nuclear elements) 
sequences in the detected intron sequence. It has been suggested that LINE sequences could be 
another factor contributing to the recombination involved. Even a 10-fold lower copy number of 
LINE elements compared to Alu sequence would be more than enough to cause recombination. It 
has been oberserved that LINE/LINE (L/L) recombination is usually involved in larger region 
[120]. 
To explain the recombination mechanisms which cause the second hit in tumors from HNPCC 
patients, the breakpoints of respective deletions have to be determined. Unfortunately, fresh 
tumor materials were not available to further assess this issue.  
 
In conclusion, our analysis of cancer specimens from two independent sets of Swiss and Finnish 
MLH1/MSH2 deletion carriers and analysis of one de novo case revealed high frequency of 
somatic mutation identical to the ones in the germline as a common second hit in CRCs. This type 
of inactivation of the wild type allele is also considered as a common second hit in extra colonic 
HNPCC associated tumors. Chromosome specific marker analysis implies that loss of the wild-
type allele predominantly occurs through locus-restricted recombination events, i.e., gene 
conversion rather than mitotic recombination or deletion of the respective gene locus. This was 
also confirmed by the result of a colorectal cancer from a patient with de novo germline mutation 
(c.666dupA) in MLH1 gene. 
 
Characterization of somatic hits in attenuated Familial Adenomatous Polyposis (aFAP) 
The ‘first hit –second hit’ association in FAP syndrome has been discussed in several reports 
[97,122]. In this thesis, we collaborated with nine research groups to do a detailed investigation in 
AFAP patients whose germline mutation are located at the very 5’ end or 3’end of the APC gene. 
In total, 235 tumors from 35 patients (16 families) with a variety of AFAP associated germline 
mutations were involved in the investigation.  A number of methods have been used to detect and 
confirm the mutations that were found in the tumors of all the patients involved. These analytical 
methods included dHPLC, direct DNA sequencing, SSCP, MLPA and site restricted cloning.   
The study showed that two somatic mutations, including loss or mutation of the germline mutant 
allele could occur (‘three hits’) in AFAP tumors. The ‘third hit’ probably initiated tumorigenesis. 
We found when the mutation happened at exon 9 of APC gene, a ‘third hits’ is very common. 
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There are six exon 9 mutant families involved in this study, almost all tumors have been found 
with the ‘third hits’.  Most ‘third hits’ left three 20-amino acid repeats on the germline mutant 
APC allele with LOH of the wild-type allele. By contrast, the ‘third hit’ was much more rare in 
patients with 5’ and 3’ germline mutation. Around 15-20% 5’ APC mutation carriers seem to 
acquire ‘three hits’. The frequency of ‘third hits’ in the patients with 3’ mutation is similar to the 
patients with 5’ mutation. 
Overall, these AFAP tumors studies provide an understanding why these patients had fewer 
polyps than classical FAP patients due to ‘three Hits’ inactivation of APC gene.  In conclusion, 
the genetic analysis of AFAP patients has revealed a novel mechanism to the genotype phenotype 
association in their tumor syndrome. For some AFAP adenomas, three hits are needed for 
tumorigensis. 
 
In summary, the understanding of the interdependence and the mechanisms involved in the 
acquisition of mutations is essential to our knowledge on tumor initiation and tumor progression 
in hereditary colorectal cancers as well as in sporadic cancers. This should help us ultimately to 
identify new potential target areas for the cancer therapy and design new efficient drugs to cure 
cancer.  
The knowledge on germline and somatic mutations may be used in the future to create 
personalized chemotherapeutic strategies and eventually prevent susceptible individuals from 
cancer.   
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APPENDIX   I 
Sequences and annealing temperatures of all primers  
 
Table 1: Primer sequences applied for microsatellite marker analysis  
Map 
Gene 
Marker 
Name Direction Sequence 
Product 
length 
Annealin
g TmºC 
Labelled 
Dye 
MSH2  D2s288  Forward primer agggccttgctctggatt  276-284 52 6-FAM 
  Reverse primer  ggccagtgattgttcccc   
 D2s2227 Forward primer gacgtgtccatctctgaat 207-221 52 6- FAM 
  Reverse primer  gcagtttctcggaataacca   
 D2s 123 Forward primer aaacaggatgcctgccttta 197 -227 52 6-FAM 
  Reverse primer  ggactttccacctatgggac   
 D2s2369 Forward primer ctgacctgaacttgtgcc 242-256 52 6-FAM 
  Reverse primer  tggggctttccacatt   
 Bat 26 Forward primer tgactacttttgacttcagcc 100-120 55 HEX 
    Reverse primer  aaccattcaacatttttaaccc     
MLH1  D3s 1597 Forward primer agtacaaatacacacaaatgtctc 162-180 50 6-FAM 
  Reverse primer  gcaaatcgttcattgct   
 D3s3611 Forward primer gctacctctgctgagcat 107-137 50 6-FAM 
  Reverse primer  tagcaagactgttgggg   
 D3s3594 Forward primer caatgggctcatcgca 261-279 50 HEX 
  Reverse primer  cttggaatagtgggccaga   
 D3s 3601 Forward primer cagttaccttgatagactggtagtg 239-253 50 6-FAM 
  Reverse primer  gagatttagttgactcacccac  
 D3s3589 Forward primer aagcaatattttctaccactttct 235-245 50 HEX 
    Reverse primer  tctgagccaccagcac     
APC D5s299 Forward primer gctattctctcaggatcttg 156-182 55 6-FAM 
  Reverse primer  gtaagccaggacaagatgacag  
 D5S82 Forward primer cccaattgtatagatttagaagtc 169-179 55 HEX 
  Reverse primer  cccaattgtatagatttagaagtc  
 D5s346 Forward primer atgaccaccaggtaggtgtatt 215 55 HEX 
  Reverse primer  actcactctagtgataaatcggg  
 D5s318 Forward primer agcagataagacagtattactagtt 96-106 55 6-FAM 
    Reverse primer  tctagaggatcttccctctt     
 Bat 25 Forward primer ccatcggtagaactaatttc  116-128 55 HEX 
  Reverse primer  tcgcctccaagaatgtaagt   
 Bat 40 Forward primer attaacttcctacaccacaac 128 55 6-FAM 
    Reverse primer  gtagagcaagaccaccttg     
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Table 2: Primer  sequences of MLH1 exons for QMPA  
MLH1 
exons Forward primers 5'-3'  Reverse primers 5'-3'  
Product 
length(bp) 
1 ttcggcggctggacgagac tcgtagcccttaagtgagc 134 
2 tacattagagtagttgcaga agagaaaggtcctgactc 224 
3 taacagaaagaagatctgg acaatgtcatcacaggagg 157 
4 ctttccctttggtgaggtga attactctgagacctagg 224 
5 gattttctcttttccccttggg acaaagcttcaacaatttactct 187 
6 ttctgttcaggtggaggacc tggactgtacctgccaacaa 112 
7 caagcagcaaacttacaaga accaccaccaactttatgag 175 
8 cactacccaatgcctcaacc acatgattcacgccacagaa 288 
9 gggaaggaaccttgtgtttt cataaaattccctgtgggtg 266 
10 gttttgaactggttgctttc gtggtgtatgggattcactc 247 
11 tttgaccactgtgtcatctg acctgggtgaagtacatcct 271 
12 aatccacaacaagtctgacc aaatgcatcaagcttctgtt 107 
13 tttgagtctccaggaagaaa ctgtagtgccactctgacaa 139 
14 ttttgttttgcagttctcc tagctctgcttgttcacaca 157 
15 cttctcccattttgtccc aaatttcagaagtgaaaagga 177 
16 ttgctccttcatgttcttgc tccaaagagaaatagtctgc 185 
17 taccccttctgattgacaac atctgcttgatcactgacct 92 
18 agtctgtgaatctccgttttaga cagtgtgcatcaaccactgta 210 
19 aatcctcttgtgttcaaggc tgcaggatatttccaatcttc 298 
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Table 3: Primer sequences of MSH2 exons of QMPA  
MSH2 
exons Forward primer  Reverse primer 
product 
length(bp) 
1  ttcgtgcgcttcttcag accccctgggtcttgaac 134
2 cttaaggagcaaagaatctgc atgccacctaccaatcattc 154
3 tatattgtcagcttccattggt gggtaaaacacattcctttgg  186
4 catcatatcagtgtcttgcac cttgaggtcctgataaatgtc 221
5 tactgtctgcggtaatcaagt taaaggtaagggctctgac 131
6 ttaatgagcttgccattct gagaggctgcttaatccac 151
7 acaagcagcaaacttacaaga gaccaccaccaactttatgag 175
8 ttccaagtttcaggaaatga gctttcttaaagtggcctttg 111
9 ctgacttggaaaagaagatgc cgggcttgtttaaatgacatc 226
10 tttcgtgtaacctgtaaggaa ggggctatttaacaaatggtg 256
11 agatactttggatatgtttca ccaggtgacattcagaaca 225
12 tttaggaaatgggttttgaat atgcctggatgcttttaat 271
13 cattgtggactgcatcttagc caaagtccacaggaaaacaac 340
14 gctacgatggatttgggttag tttcccattaccaagttctg 238
15  gvctgtctcttctcatgctgt tgatagcacttctttgctgct 214
16 tctgtccaaggtgaaacaaa cccattactgggatttttcac 160
 
Table 4 : Primer sequences of  the APC mutation cluster region (MCR). PCR products range 
between 90-150bp in length. All fragments share the same annealing temperature 60°C.  
MCR 
Fragments Forward primer 5'-3' Reverse primer 5'-3' 
1  tgcaaagtttcttctattaaccaa  atttaggtgacactattctgcttcctgtgtcgtctg 
2 ttcattatcatctttgtcatcagc  atttaggtgacactattggaacttcgctcacaggat 
3 gcagaaataaaagaaaagattggaa  atttaggtgacactatctttgtgcctggctgattct 
4 ctagaaccaaatccag cagact  atttaggtgacactatgaacatagtgttcaggtggactttt 
5 agcgaaatctccctccaaaa  atttaggtgacactatctggcaatggaacgactctc 
6  cccactcatgtttagcagatg  atttaggtgacactatgtttgtccagggctatctgg 
7  tggaatggtaagtggcattat  atttaggtgacactatcagcagtaggtgctttatttttagg 
8 tcctcaaacagctcaaacca  atttaggtgacactatagcatctggaagaacctgga 
9  aagcaagctgcagtaaatgct  atttaggtgacactatatggctcatcgaggctca 
10  aagtactccagatggattttcttg  atttaggtgacaqctatggctgctctgattctgtttca 
11  atgcctccagttcaggaaaa  atttaggtgacactattcaatatcatcatcatctgaatcatc 
12  aaaaactattgactctgaaaaggac atttaggtgacactatggtggaggtaattttgaagca 
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Table 5: Primer sequences of MYH  used for MYH dHPLC analysis and sequencing. 
MYH exons Forward primers 5'-3' Reverse primer 5'-3' 
1 tgaaggctacctctgggaag  aggagacggaccgcaag 
2 ggctgggtctttttgtttca  gggccacaacctagttcctt 
                     3a   actgtgtcccaagaccctgat  ttggtcgtaccagcttagca 
                    3b agctgaagtcacagccttcc  cacccactgtccctgctc 
4 cctccaccctaactcctcatc  aaagtggccctgctctcag 
5 caggtcagcagtgtcctcat  gtctgacccatgacccttcc 
6 caggtcagcagtgtcctcat  gtctgacccatgacccttcc 
7 cgggtgatctctttgacctc  gttcctaccctcctgccatc 
8 tcttgagtcttgcactccaatc  aaagtgggggtgggctgt 
9 gctaactctttggcccctct  cacccttgttaccccaacat 
10 ctgcttcacagcagtgttcc  gacttctcactgccccttcc 
11 acactcaaccctgtgcctct  ggaatggggcttctgactg 
                   12a acttggcttgagtagggttcg  ggctgttccagaacacaggt 
                   12b gagtggtcaacttccccaga  cacgcccagtatccaggta 
13 agggaatcggcagctgag  gctattccgctgctcactta 
14 aggcctatttgaaccccttg caacaaagacaacaaaggtagtgc 
15 ccctcacctccctgtcttct tgttcacccagacattcgtt 
                   16a actacaaggcctccctccttc  gctgcactgttgaggctgt 
                   16b gccagcaagtcctggataat  acatagcgagacccccatct 
 
Table 6: PTT primer sequences for MSH2/MLH1 
MSH2  Forward primer Reverse Primer Product length  
Fragment 1 
ggatcctaatacgactcactatagggagaccaccat
ggcggtgcagccgaa catcctgggcttcttcata tctgttttat 1.7kb 
Fragment 2 
ggatcctaatacgactcactatagggagaccaccc   
ttggcttggacctggcaaac 
tcaatattaccttcattccattactggg
attt 1.3kb 
    
    
MLH1  Forward primer  Reverse primer Product length  
Fragment 1 
ggatcctaatacgactcactatagggagaccaccat
gac atctagacgtttcctt aaatgcatcaagcttctgttc 1.2kb 
Fragment 2 
ggatcctaatacgactcactatagggagaccaccat
ggtgcagcagcacatcgaga cacagtgcataaataaccat 1.3kb 
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APPENDIX  II: 
dHPLC conditions of different genes 
Table 7: dHPLC analysis conditions for MYH exon. Each exons has two different melting 
temperatures Tm1 (°C) and Tm2 (°C)  
MYH exons   Tm 1(°C) 
 
Tm2( °C) 
1 62.7 66.7 
2 60.9 63.9 
3a 61.7 62.7 
3b 62.5 64.5 
4 61.4 62.4 
5 61.7 63.7 
6 60.4 63.4 
7 60.7 64.7 
8 61.1 66.1 
9 60.9 64.9 
10 61.5 65.5 
11 62.2 64.2 
12a 62.5 64.5 
12b 62.1 65.1 
13 63.6 65.6 
14 59.6 63.6 
15 59.6 63.6 
16a 60.8 62.8 
16b 56.3 61.3 
 
Table 8: dHPLC analysis conditions (heteroduplex fragment analysis) for the APC mutation 
cluster region. Each fragment has two different melting temperatures Tm1(°C) and Tm2(°C)  
        MCR Fragments          Tm1( °C )      Tm2 (°C) 
1 54.3 56.3 
2 57.6 58.1 
3 58 60.5 
4 59.4 60 
5 59.7 60.5 
6 59.1 59.6 
7 58.5 60.5 
8 58.5 60.5 
9 59.2 60.2 
10 58 58.8 
11 56.1 57.9 
12 55.5 57.8 
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APPENDIX  III    
Multiplex Ligation dependent Probe Amplification –MLPA   
MLPA protocol 
1. DNA-Denaturation : 
      Dilute the DNA-sample (250 ng DNA) with TE to 5 µl.  
2. Heat 5 minutes at 98°C; Cool to 25°C before opening the thermal cycler. 
3. Hybridisation of SALSA probes : Add 1.5 µl SALSA Probe-mix (black cap) add 1.5 µl 
MLPA buffer (yellow cap). Mix with care. Incubate 1 minute at 95°C, 
4. hold on 60°C for 16 hours (over night) .  
5. Ligation reaction : Reduce the temperature of the thermal cycle to 54°C.  add 32 µl Ligase-65 
mixt to each sample and mix.  
      Mix: Ligase-65 mix (made less than 1 hr. before use and stored on ice) includes 3 µl Ligase-65   
      buffer A (transparent cap) and 3 µl Ligase-65 buffer B (white cap) ,plus 25 µl Water, 1 µl     
      Ligase-65 (brown cap) 
6. Incubate it 15 minutes at 54°C, then heat 5 minutes at 98°C. 
7. PCR amplification : Mix: 1 µl SALSA PCR-primers (purple cap) and 1 µl SALSA enzyme 
dilution buffer (blue cap) were added to 5ul MLPA ligation reaction .Then  0.25ul SALSA PCR 
enzyme and distilled water were added to fill the final volume up to 20 µl . 
8. PCR reaction: 95°C  5minutes, 95°C30 seconds;  60°C30 seconds;  72°C   60 seconds, run the 
program for 35 cycles ,then end the incubation at 72°C for 20 minutes.  
9. Fragment analysis on genetic analyzer 
      Sample preparation: 2µl MLPA PCR products mixed with 12 µl deionized formamide        
      (Applied Biosystems, Rotkreuz, Switzerland) and 0.5 µl ROX 500 (Applied Biosystems,  
      Rotkreuz, Switzerland).The mixture was denatured at 90°C 2 minutes, then puton ice for 2  
      minutes. The samples were loaded on ABI PRISM 310 sequence analysis machine .  
      Sample analysis condition : GC Matrix A  
 
 
Table 9: Detail information of MLH1/MSH2 salsa probes 
    Chromosome Location   
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Length (nt) MLPA MLH1/MSH2 probe Control MLH1 MSH2 
64-70-76-82 DQ-control bands*    
94 Synthetic Control probe 2q14   
130 Control probe0797-L0463 5q31   
136 Control probe 0981-L0566 10p11   
142 MLH1 probe 0886-L0474   exon 1  
148 MSH2 probe 1027-L0599    exon 1 
154 MLH1 probe 1008-L0577   exon 2  
160 MSH2 probe 0906-L0494    exon 2 
166 MLH1 probe 0888-L0476   exon 3  
172 MSH2 probe 1029-L0601   exon 3 
178 MLH1 probe 0889-L0477   exon 4  
184 MSH2 0908-L0496    exon 4 
193 Control probe 0976-L0563 11p13   
202 MLH1 probe 0890-L0478   exon 5  
211 MSH2 probe 0909-L0497   exon 5 
220 MLH1 probe 0891-L0479  exon 6  
229 MSH2 probe 0910-L0498   exon 6 
238 MLH1 probe 0892-L0480  exon 7  
247 MSH2 probe 0911-L0499   exon 7 
256 MLH1 probe 0893-L0481  exon 8  
265 MSH2 probe 0912-L0582    exon 8 
274 MLH1 probe 0894-L0482  exon 9  
283 Control probe 0438-L0003 17q21   
292 MSH2 probe 0913-L0583   exon 9 
301 MLH1 probe 0895-L0483  exon 10  
310 MSH2 probe 0914-L0584    exon 10 
319 MLH1 probe 0896-L0484   exon 11  
328 MSH2 probe 0915-L0503    exon 11 
337 MLH1 probe 0897-L0485   exon 12  
346 MSH2 probe 0916-L0504   exon 12 
355 MLH1 probe 0898-L0486  exon 13  
364 MSH2 probe 1013-L0575   exon 13 
373 Control probe 0681-L0154 4q25   
382 MLH1 probe 0899-L0586   exon 14  
391 MSH2 probe 0918-L0506   exon 14 
400 MLH1 probe 0900-0488  exon 15  
409 MSH2 probe 0919-L0585   exon 15 
418 MLH1 probe 1009-L0576  exon 16  
427 MSH2 probe 1053-L0627   exon 16 
436 MLH1 probe 1030-L0602  exon 17  
445 MLH1 probe 1031-L0603  exon 18  
454 MLH1 probe 0904-L0492  exon 19  
463 Control probe 0979-L0568 10p14   
472 Control probe 0980-L0567 11p12     
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Table 10: Sequences detected by the probes and distances between the MLH1 exons. 
Length 
(nt) 
Salsa 
Probe # 
MLH1 
exon Ligationsite Sequence at Ligation site 3q22.1 
Distance 
to next 
exon 
  startcodon  22-24   
142 
0886-
L0474 exon 1 28-29 AAAATGTCGT-TCGTGGCAGG 3.1 kb 
154 
1008-
L0577 exon 2 206-207 TTCAGATCCA-AGACAATGGC 4.3 kb 
166 
0888-
L0476 exon 3 286-287 CAGTCCTTTG-AGGATTTAGC 3.4 kb 
178 
0889-
L0477 exon 4 350-351 TAAGCCATGT-GGCTCATGTT 2.6 kb 
202 
0890-
L0478 exon 5 450-451 ACCATGTGCT-GGCAATCAAG 1.8 kb 
220 
0891-
L0479 exon 6 487-488 GAGGACCTTT-TTTACAACAT 3.0 kb 
238 
0892-
L0480 exon 7 587-588 ACAATGCAGG-CATTAGTTTC 0.2 kb 
256 
0893-
L0481 exon 8 641-642 TTAGGACACT-ACCCAATGCC 2.3 kb 
274 
0894-
L0482 exon 9 743-744 TAGCCTTCAA-AATGAATGGT 3.0 kb 
301 
0895-
L0483 exon 10 842-843 CCTTGAGAAAAGCCATAGAA 2.8 kb 
319 
0896-
L0484 exon 11 1013-1014 AGCACATCGAGAGCAAGCTC 5.4 kb 
337 
0897-
L0485 exon 12 1305-1306 GCAGCAAGATGAGGAGATGC 2.9 kb 
355 
0898-
L0486 exon 13 1488-1489 CCGAAAGGAAATGACTGCAG 11.4 kb 
382 
0899-
L0586 exon 14 1622-1623 TGGGCTGTGTGAATCCTCAG 2.0 kb 
400 
0900-
0488 exon 15 1715-1716 AGATACTCAT-TTATGATTTT 5.2 kb 
418 
1009-
L0576 exon 16 1790-1791 TGCTTGCCTTAGATAGTCCA 1.0 kb 
436 
1030-
L0602 exon 17 1995-1996 CTTCATTCTTCGACTAGCCA 0.4 kb 
445 
1031-
L0603 exon 18 
2092-2091 
(Rev.) CCTCAGATATGTACTGCTTC 1.6 kb 
454 
0904-
L0492 exon 19 2177-2178 TGGAACACATTGTCTATAAA   
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Table 11: Sequences detected by the probes and distances between the MSH2 exons.  
MLH1 
Length 
(nt) 
SALSA 
MLPA 
probe exon 
Ligation site  
U03911 
Partial sequence (20 nt adjacent 
to ligation site) 
Distance to 
next exon 
  startcodon  4-6   
190 
6343-
L5729 exon 1 (-28 - -29) GTCGCGCATTTTCTTCAACC 0.1 kb 
 148* 
1027-
L0599  exon 1 130-131 GGCGACTTCTATACGGCGCA 5.1 kb 
172 
1029-
L0601 exon 3 454-455 GTGGGTGTTAAAATGTCCGC 2.3 kb 
184 
0908-
L0496  exon 4 741-742 GTTGTTGAAAGGCAAAAAGG 1.8 kb 
211 
0909-
L0497 exon 5 821-822 TGTCTGCGGTAATCAAGTTT 2.0 kb 
229 
0910-
L0498 exon 6 996-997 CTTGCTGAATAAGTGTAAAA 13.5 kb 
247 
0911-
L0499 exon 7 1172-1173 TTAACCGACTTGCCAAGAAG 15.7 kb 
265 
0912-
L0582  exon 8 1327-1328 CCTCTTACTGATCTTCGTTC 17.4 kb 
292 
0913-
L0583 exon 9 1414-1415 TTCCTTGTAAAACCTTCATT 3.6 kb 
310 
0914-
L0584  exon 10 1536-1537 CAAACAGATTAAACTGGATT 4.3 kb 
328 
0915-
L0503  exon 11 
1710-1709 
(rev.) TTCTTCATATTCTGTTTTAT 4.2 kb 
346 
0916-
L0504 exon 12 1858-1859 CCTGTTCCATATGTACGACC 1.3 kb 
364 
1013-
L0575 exon 13 2074-2075 ATGGCCCAAATTGGGTGTTT 1.9 kb 
391 
0918-
L0506 exon 14 2281-2282 TACGATGGATTTGGGTTAGC 2.4 kb 
409 
0919-
L0585 exon 15 2564-2565 TTGAGGAGTTTCAGTATATT 1.9 kb 
427 
1053-
L0627 exon 16 2640-2641 GTTTCAGCAAGGTGAAAAAA   
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